oseltamivir has been researched along with Orthomyxoviridae Infections in 215 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (0.93) | 18.2507 |
| 2000's | 45 (20.93) | 29.6817 |
| 2010's | 141 (65.58) | 24.3611 |
| 2020's | 27 (12.56) | 2.80 |
| Authors | Studies |
|---|---|
| Boltz, DA; Douglas, A; Govorkova, EA; Ilyushina, NA; Webster, RG; Yilmaz, N | 1 |
| Abed, Y; Baz, M; Boivin, G; Nehmé, B | 1 |
| Barr, IG; Holien, JK; Hurt, AC | 1 |
| Chen, CA; Chen, CL; Cheng, TJ; Cheng, YS; Fang, JM; Hsieh, WC; Hu, OY; Huang, PW; Jan, JT; Lin, WH; Shie, JJ; Tarbet, EB; Wang, SY; Weinheimer, S; Wong, CH | 1 |
| Bandarage, UK; Bennani, YL; Bennett, HB; Bethiel, RS; Boyd, MJ; Bral, C; Byrn, RA; Charifson, PS; Clark, MP; Court, JJ; Davies, I; Deng, H; Dorsch, WA; Duffy, JP; Farmer, LJ; Gao, H; Germann, U; Gu, W; Jackson, K; Jacobs, DH; Jacobs, M; Jiang, M; Jones, SM; Kennedy, JM; Ledeboer, MW; Ledford, B; Leeman, JR; Liang, J; Maltais, F; McNeil, C; Memmott, C; Murcko, M; Nezami, A; Nti-Addae, K; Perola, E; Rijnbrand, R; Salituro, FG; Taylor, WP; Tsai, A; Wang, T; Wannamaker, MW; Zhang, Y | 1 |
| Hao, C; Jiang, T; Wang, W; Yin, R; Yu, R; Zhang, L; Zhang, M | 1 |
| Li, H; Li, M; Wang, S; Xiao, S; Xu, R; Zhang, L; Zhang, Y; Zhou, D | 1 |
| Ando, Y; Kawai, M; Kida, H; Kobayashi, M; Matsuno, K; Naito, A; Nobori, H; Noshi, T; Okamatsu, M; Sakoda, Y; Sanaki, T; Sato, A; Shishido, T; Taniguchi, K; Toba, S; Yoshida, R | 1 |
| Chen, Z; Hou, G; Jiang, L; Jiang, Z; Shi, S; Wang, H; Yan, H; Zheng, X; Zhou, J | 1 |
| Briestenská, K; Mikušová, M; Tomčíková, K; Varečková, E | 1 |
| Bao, L; Bao, Y; Cui, X; Gao, S; Geng, Z; Guo, S; Shi, Y; Yao, R; Zhao, R; Zhou, L | 1 |
| Casto, AM; Chu, HY; Englund, JA; Han, PD; Hughes, JP; Link, AC; Martinez, MA; Nackviseth, C; Nwanne, G; Pfau, B; Rogers, JH; Shendure, J; Sugg, N; Uyeki, TM; Wolf, CR | 1 |
| Chen, YW; Li, SG; Liang, H; Pang, YS | 1 |
| Cui, QH; DU, RK; Geng, ZK; Li, YQ; Tian, JZ | 1 |
| Embury-Hyatt, C; Feldmann, F; Feldmann, H; Gren, J; Grolla, A; Jones, SM; Kakugawa, S; Kawaoka, Y; Kiso, M; Kobasa, D; Taylor, T | 1 |
| Chen, X; Deng, L; Liu, P; Pang, P; Shi, Y; Wu, S; Xiao, Y; Xu, H | 1 |
| Bai, Q; Fei, GH; Ji, S; Shen, JL; Wang, S; Wu, X; Zhang, DW | 1 |
| Dai, Z; Fan, K; Liu, L; Yang, M; Yu, Q; Zhang, L | 1 |
| Hurt, AC; Mifsud, EJ; Ming-Kay Tai, C; Oh, DY; Rossignol, JF; Tilmanis, D | 1 |
| Cao, R; Dai, Q; Guo, X; Li, W; Li, X; Li, Y; Xia, Q; Xu, K; Yan, Y; Yang, J; Yang, K; Zhao, L; Zhong, W; Zou, G | 1 |
| Baba, K; Kamimori, H; Kitano, M; Kiyota, K; Matsuzaki, T; Mizutare, T; Naito, A; Noda, T; Oka, R; Sato, A; Sato, K; Shishido, T; Yoshida, R; Yoshida, Y | 1 |
| Barr, IG; Hurt, AC; Koszalka, P; Mifsud, E; Rossignol, JF; Tilmanis, D | 1 |
| Durvasula, R; Goicoechea, S; Kempaiah, P; Kumar, S; Pearce, CM; Rathi, B | 1 |
| Anderson, DE; Barr, IG; Farrukee, R; Gunalan, V; Hibberd, M; Hurt, AC; Lau, GY; Maurer-Stroh, S; Messling, VV; Oh, DY; Tai, CM | 1 |
| Hensen, L; Hurt, AC; Kedzierska, K; Kedzierski, L; Koutsakos, M; Mercuri, F; Mifsud, E; Nüssing, S; Rossignol, JF; Wang, Z | 1 |
| Arish, M; Naz, F | 1 |
| Baratelli, M; Casas, I; Córdoba, L; Fraile, L; Majó, N; Martínez, J; Martínez-Orellana, P; Martorell, JM; Migura-Garcia, L; Montoya, M; Pérez, M; Pozo, F; Vidaña, B | 1 |
| Chen, Y; Ding, M; Jiang, X; Lan, K; Lavillete, D; Li, H; Li, S; Liu, Y; Shan, J; Shang, W; Shen, Z; Sun, Y; Tong, Y; Wang, R; Wang, Y; Wu, Y; Xiao, G; Xiong, R; Xu, K; Xu, L; Zhang, L; Zhao, Y; Zhao, Z; Zhu, L; Zou, G | 1 |
| Jiang, H; Xu, Y | 1 |
| Abed, Y; Baz, M; Boivin, G; Checkmahomed, L; Padey, B; Pizzorno, A; Rosa-Calatrava, M; Terrier, O | 1 |
| Achanta, M; Ashar, HK; Chow, VTK; Malayer, JR; Maram, P; Pulavendran, S; Rudd, JM; Snider, TA; Teluguakula, N | 1 |
| Bai, Y; Jones, JC; Wong, SS; Zanin, M | 1 |
| Durymanov, AG; Goncharova, NI; Gudymo, AS; Ilyicheva, TN; Kolosova, NP; Kovrizhkina, VL; Marchenko, VY; Onkhonova, GS; Ryzhikov, AB; Shvalov, AN; Susloparov, IM; Svyatchenko, SV; Tregubchak, TV | 1 |
| Antigua, KJC; Baek, YH; Choi, WS; Choi, YK; Jeong, JH; Kim, B; Kim, CH; Kim, CI; Kim, EG; Oh, S; Park, JH; Song, MS | 1 |
| Fang, Q; Feng, Z; Gao, R; Huang, W; Li, X; Liu, J; Liu, L; Tang, J; Wang, D; Xu, C; Zhang, S | 1 |
| Cáceres, CJ; Cárdenas-García, S; Carnaccini, S; Gay, LC; Geiger, G; Hu, Y; Ma, C; Perez, DR; Rajao, D; Tan, H; Wang, J; Wu, X; Zhang, QY | 1 |
| Dagley, A; Smee, DF; Tarbet, EB | 1 |
| Kallewaard, NL; Lakdawala, S; McAuliffe, JM; Paskel, M; Paules, CI; Subbarao, K; Vogel, L; Zhu, Q | 1 |
| Chang, CS; Chen, TC; Dutta, A; He, YC; Huang, CT; Huang, YL; Hung, CY; Lin, CY; Lin, YC | 1 |
| Han, H; Lin, H; Lu, G; Pang, Y; Qi, J; Qiu, H; Wang, X; Yang, R; Yang, Y; Yu, L; Zhang, Y; Zhu, W | 1 |
| Abed, Y; Boivin, G; Fage, C; Pizzorno, A; Rhéaume, C | 1 |
| Bank, C; Bolon, DN; Finberg, RW; Jensen, JD; Kowalik, TF; Liu, P; Matuszewski, S; Ormond, L; Renzette, N; Wang, JP; Zeldovich, K | 1 |
| Friedrich, TC; Fukuyama, S; Hasegawa, H; Imai, M; Ito, M; Itoh, Y; Iwatsuki-Horimoto, K; Kawakami, E; Kawaoka, Y; Kiso, M; Lopes, TJS; Moncla, LH; Nakajima, N; Neumann, G; Ogasawara, K; Tomita, Y; Uraki, R; Watanabe, T; Yamada, S; Yamayoshi, S | 1 |
| Cho, J; Jang, EY; Kang, C; Kim, K; Lee, CH; Lee, JY; Lee, MS; Yi, H | 1 |
| Alefantis, T; Anderson, SF; Bi, X; Cai, X; Cao, J; Chen, H; Chen, J; Chen, Y; Fang, M; Kleanthous, H; Li, R; Luo, W; Shen, C; Stegalkina, S; Wai-Kuo Shih, J; Wang, G; Xia, N; Yang, K; Yu, H; Yuan, Q; Zhang, J; Zhang, L; Zhang, M; Zheng, Q; Zheng, Z | 1 |
| Govorkova, EA; Jones, JC; Marathe, BM; Mostafa, HH; Pascua, PNQ; Russell, CJ; Vogel, P; Webby, RJ | 1 |
| Hasegawa, H; Ito, M; Kawaoka, Y; Kiso, M; Lopes, TJS; Nakajima, N; Neumann, G; Yamashita, M; Yamayoshi, S | 1 |
| Gegova, GA; Pavlova, EL; Simeonova, LS | 1 |
| Bamba, D; Galarneau, JR; Growcott, EJ; Leonard, VHJ; Osborne, CS; Schul, W; Stein, D | 1 |
| Abed, Y; Boivin, G; Carbonneau, J; Checkmahomed, L; Dufresne, SF; Fage, C; Kobinger, G; Tu, V; Venable, MC | 1 |
| Go, YY; Jang, Y; Kim, M; Kwon, OS; Lee, HW; Park, MS; Park, S; Shin, JS; Yoon, YS | 1 |
| Baz, M; Boivin, G; Carbonneau, J; Cavanagh, MH; Rhéaume, C | 1 |
| Ando, Y; Baba, K; Fukao, K; Higuchi, N; Ikeda, M; Kitano, M; Matsumoto, K; Naito, A; Noda, T; Noshi, T; Shishido, T; Yamamoto, A | 1 |
| Beale, DJ; Dunn, MS; Hurt, AC; Karpe, AV; Oh, DY; Palombo, EA; Tai, C; Tilmanis, D | 1 |
| Jiang, H; Shen, S; Shi, Y; Su, X; Zhao, J; Zhu, M | 1 |
| Hoshino, K; Kubo, S; Tomozawa, T; Yamashita, M | 1 |
| Akhilesh, R; Chow, VTK; Malayer, JR; Maram, P; Pulavendran, S; Rudd, JM; Teluguakula, N; Thomas, PG | 1 |
| Carnoy, C; Cayet, D; Dubuisson, J; Georgel, AF; Paget, C; Pizzorno, A; Rosa-Calatrava, M; Sencio, V; Sirard, JC; Trottein, F | 1 |
| Ando, Y; Fukao, K; Kawai, M; Kitano, M; Naito, A; Noda, T; Noshi, T; Sato, A; Shishido, T; Yoshida, R | 1 |
| Belser, JA; Katz, JM; Szretter, KJ; Tumpey, TM | 1 |
| Itoh, Y; Kanazu, T; Kitano, M; Kobayashi, M; Kodama, M; Sato, A; Yoshida, R | 1 |
| Baek, YH; Cho, WK; Choi, YK; Decano, A; Kim, EH; Kim, SM; Kwon, HI; Lee, KJ; Lim, GJ; Ma, JY; Park, SJ; Pascua, PN; Song, MS | 1 |
| Bauer, K; Duerrwald, R; Schlegel, M; Schmidtke, M; Vissiennon, T; Wutzler, P | 1 |
| Boonnak, K; Orandle, M; Subbarao, K; Talor, E; Vogel, L; Zimmerman, D | 1 |
| Imanishi, J; Kita, M; Mazda, O; Ohgitani, E | 1 |
| Bae, JY; Han, SZ; Heo, J; Hwang, MW; Kim, D; Kim, JI; Lee, I; Lee, S; Park, MS; Park, S | 1 |
| Bao, L; Chen, H; Deng, W; Li, F; Lv, Q; Qin, C; Xu, L; Xu, Y; Yao, Y; Yu, P; Yuan, J; Yuen, KY | 1 |
| An, L; Chen, X; Liao, Q; Liu, R; Qian, Z | 1 |
| Homma, T; Imamura, Y; Iwanaga, N; Izumikawa, K; Kajihara, T; Kakeya, H; Kitano, M; Kohno, S; Kurihara, S; Miyazaki, T; Nakamura, S; Seki, M; Tanaka, A; Yanagihara, K | 1 |
| Abed, Y; Boivin, G; Pizzorno, A; Rhéaume, C | 1 |
| Barclay, WS; Bean, TJ; Bruce, C; Carroll, MW; Dimmock, NJ; Dove, BK; Dowall, S; Easton, AJ; Hallis, B; Marriott, AC; Newman, E; Pearson, G; Plank, J; Rayner, E; Ryan, KA; Silman, NJ; Taylor, I; Whittaker, CJ | 1 |
| Crawford, S; Hamilton, S; Hurst, BL; Luttick, A; Ng, WC; Pryor, M; Smee, DF; Tarbet, EB; Tucker, SP; Vollmer, AH | 1 |
| Deryabin, PG; Galegov, GA; Konstantinova, ID; L'vov, DK; Miroshnikov, AI; Muzyka, IS | 1 |
| Bae, JY; Baek, LJ; Cheong, HJ; Heo, J; Hwang, MW; Jang, SI; Kim, D; Kim, H; Kim, JI; Lee, I; Lee, S; Park, MS; Park, S; Song, JW; Song, KJ | 1 |
| Abed, Y; Baz, M; Boivin, G; Carbonneau, J; Corbeil, J; Hamelin, MÈ; Pizzorno, A; Plante, PL | 1 |
| Chang, FY; Chesnokov, AP; Cox, NJ; Davis, CT; De La Cruz, JA; Fry, AM; Gubareva, LV; Jones, J; Liu, MT; Marjuki, H; Mishin, VP; Nguyen, HT; Sleeman, K; Tamura, D; Villanueva, JM; Wu, HS | 1 |
| Chen, J; Chow, VT; Leung, NH; Limmon, GV; Rajapakse, JC; Xu, S; Yin, L; Yu, H; Zheng, D | 1 |
| Bao, L; Deng, W; Gao, Z; Gu, S; Li, F; Li, Y; Lv, Q; Qin, C; Xu, L; Xu, Y; Yao, Y; Yu, P; Yuan, J; Zhu, H | 1 |
| Chen, HC; Kuo, RL; Lee, CK; Leu, CM; Lin, CN; Lin, MY; Lin, SJ; Lo, M; Lu, J; Ojcius, DM; Shih, SR; Tsai, CH | 1 |
| Cloutier, A; Garneau, É; Lesur, O; Marois, I; Richter, MV | 1 |
| Charyasriwong, S; Haruyama, T; Kobayashi, N; Matsunaga, A; Rahmasari, R; Watanabe, K | 1 |
| Bahl, J; Baranovich, T; Culhane, M; Darnell, D; Govorkova, EA; Kaplan, BS; Lowe, JF; Marathe, BM; Stigger-Rosser, E; Webby, RJ | 1 |
| Barr, IG; Hurt, AC; Oh, DY | 1 |
| Chesnokov, AP; Davis, CT; De La Cruz, JA; Fry, AM; Gubareva, LV; Marjuki, H; Mishin, VP; Villanueva, JM | 1 |
| Homma, T; Kitano, M; Kobayashi, M; Naito, A; Onishi, M; Sato, A; Taniguchi, K; Yoshinaga, T | 1 |
| De Baets, S; Fiers, W; Job, ER; Roose, K; Saelens, X; Schepens, B; Schotsaert, M; Smet, A; Van den Hoecke, S; Verhelst, J | 1 |
| Anikin, VB; Beliavskaia, SV; Galochkina, AV; Garshinina, AV; Shtro, AA; Smirnov, VS; Zarubaev, VV | 1 |
| Doi, M; Igarashi, M; Ishida, H; Ishigaki, H; Ishii, A; Itoh, Y; Kida, H; Kitagawa, N; Nakamura, S; Nakayama, M; Ogasawara, K; Okamatsu, M; Sakoda, Y; Sasamura, T; Shichinohe, S; Shiohara, M; Tsuchiya, H | 1 |
| Bird, NL; Chua, BY; Handel, A; Hurt, AC; Jackson, DC; Kedzierska, K; Oh, DY; Olson, MR; Oshansky, CM; Reading, PC; Sun, Y; Tang, L; Thomas, PG; Turner, SJ | 1 |
| Chang, SY; Hong, EH; Jeong, HG; Kim, H; Kim, JG; Kim, YJ; Ko, HJ; Kwon, BE; Kwon, Y; Lee, BR; Seo, SU; Shim, A; Song, HH; Song, JH | 1 |
| Belser, JA; Creager, HM; Katz, JM; Maines, TR; Tumpey, TM | 1 |
| Bennett, HB; Berlioz-Seux, F; Byrn, RA; Charifson, PS; Clark, MP; Germann, UA; Huang, C; Jones, SM; Leeman, JR; McNeil, CF; Nti-Addae, K; Rijnbrand, R; Tsai, AW | 1 |
| Cai, Y; Chen, W; Fang, X; Farooqui, A; Huang, L; Kelvin, AA; Kelvin, DJ; Khan, A; Lin, P; Liu, Y; Paquette, SG; Su, M; Wu, S; Zeng, T; Zhang, L | 1 |
| Bank, C; Bolon, DNA; Caffrey, DR; Finberg, RW; Jensen, JD; Jiang, L; Kowalik, TF; Liu, P; Prachanronarong, K; Renzette, N; Schiffer, CA; Wang, JP; Yilmaz, LS; Zeldovich, KB | 1 |
| Dou, J; Jin, J; Li, M; Wang, D; Wang, H; Xu, J; Yu, J; Zhou, C | 1 |
| Al-Abed, Y; Blanco, JC; Bowie, AG; Calandra, T; Dinarello, CA; Fasano, A; Gusovsky, F; Kurt-Jones, E; Lai, W; Lipsky, M; Pang, C; Patel, MC; Pletneva, LM; Roger, T; Shirey, KA; Tracey, KJ; Vogel, SN | 1 |
| Dor, D; Handel, A; Pawelek, KA; Salmeron, C | 1 |
| Boyne, MT; Chockalingam, AK; Goodwin, DG; Hamed, S; Pang, E; Patel, V; Rosenzweig, BA | 1 |
| Chen, J; Chen, X; Deng, L; Nie, J; Pang, P; Wu, S; Xu, H; Zheng, K | 1 |
| Garcia-Alcalde, F; Govorkova, EA; Marathe, BM; Najera, I; Vogel, P; Webby, RJ; Webster, RG; Wong, SS | 1 |
| Galabov, AS; Gegova, G; Mileva, M; Simeonova, L | 1 |
| Arkinstall, R; Denizot, M; Frazer, L; Haining, J; Harper, J; Herbreteau, CH; Johnson, D; Lowther, S; Middleton, D; Pasquier, A; Payne, J; Riddell, S; Saluzzo, JF | 1 |
| Ashcroft, JW; Barclay, WS; Bradley, K; Donnelly, CA; Elderfield, RA; Fernandez-Alonso, M; Frise, R; Galiano, M; Lackenby, A; Miah, S; Roberts, KL; Stilwell, P; van Doremalen, N | 1 |
| Koopmans, MP; Kuiken, T; Leijten, LM; Osterhaus, AD; Siegers, JY; Stittelaar, KJ; van Amerongen, G; van de Bildt, MM; van den Brand, JM; van Riel, D; van Run, PR | 1 |
| Collignon, B; Cutts, T; Embury-Hyatt, C; Hagan, MW; Kobasa, D; Leung, A; Ranadheera, C; Theriault, S | 1 |
| Altboum, Z; Amit, I; David, E; Gat-Viks, I; Jaitin, DA; Keren-Shaul, H; Klepfish, M; Mandelboim, M; Sagi, I; Solomonov, I; Talmi-Frank, D; Udi, Y; Winter, DR; Zhuravlev, A; Ziv, T | 1 |
| Barnard, DL; Jones, SM; Smee, DF | 1 |
| Abed, Y; Barbeau, X; Boivin, G; Carbonneau, J; Fage, C; Lagüe, P; Tu, V | 1 |
| Borshcheva, AA; Emelyanova, AG; Epstein, OI; Gorbunov, EA; Mazurkov, OY; Petrova, NV; Shishkina, LN; Skarnovich, MA; Skarnovich, MO; Tarasov, SA | 1 |
| Beerens, N; Bestebroer, TM; Cotten, M; de Jonge, HC; de Kleer, I; Fouchier, RA; Fraaij, PL; Hoebe, CJ; Houmes, RJ; Koopmans, MP; Oude Munnink, BB; Pas, SD; Phan, MV; Roosenhoff, RS; Swaan, CM; Timen, A; Tolsma, P; van den Kerkhof, JH; van Kampen, JJ; Wildschut, ED | 1 |
| Fu, LC; Lai, YN; Li, Y; Liu, N; Xu, PP; Zhang, FX; Zhao, F | 1 |
| Arthur Chen, YM; Chen, HY; Chen, KH; Huang, JC; Lee, YM; Li, MC; Liu, FT; Loh, EW; Tsai, WC; Tseng, SP; Wang, SF; Wang, WH | 1 |
| Chai, N; Chiang, N; Chiu, H; Ciferri, C; Estevez, A; Fong, R; Kamen, L; Kho, E; Lin, Z; Lupardus, P; Modrusan, Z; Nakamura, G; Park, S; Reichelt, M; Skippington, E; Stinson, J; Swem, LR; Tan, MW; Xu, M | 1 |
| Aguilar-Faisal, L; Barrón, BL; Correa-Basurto, J; Fragoso-Vázquez, MJ; García-Machorro, J; Martínez-Ramos, F; Méndez-Luna, D; Neri-Bazán, RM; Padilla-Martínez, II; Soriano-Ursúa, MA; Tolentino-López, LE; Trujillo-Ferrara, JG | 1 |
| Leyva-Grado, VH; Palese, P | 1 |
| Hino, A; Kurokawa, M; Park, YK; Shimizu, T; Tsutsumi, A; Watanabe, W | 1 |
| Boon, AC; Govorkova, EA; Hay, A; Ilyushina, NA; Webster, RG; Yilmaz, N | 1 |
| Air, GM; Gulati, S; Smith, DF | 1 |
| Bondarev, VP; Borisevich, SV; Loginova, SIa; Maksimov, VA; Nebol'sin, VE | 1 |
| Bailey, KW; Hurst, BL; Morrey, JD; Smee, DF; Wong, MH | 1 |
| Amnuoypol, S; Mungmee, C; Nagai, T; Wirotesangthong, M; Yamada, H | 1 |
| Holodniy, M; Schirmer, P | 1 |
| Belopolskaya, MV; Dugina, JL; Epstein, OI; Evtin, NK; Kabanov, AS; Kheyfets, IA; Mazurkova, NA; Sergeev, AA; Sergeev, AN; Sergeeva, SA; Shishkina, LN; Skarnovich, MO; Tarasov, SA | 1 |
| Ridenhour, BJ; Shay, DK | 1 |
| Guo, Z; He, H; Higgins, D; Li, G; Liu, Y; Liu, Z; Lu, J; Shanahan-Prendergast, L; Walsh, A; Wang, G; Zhang, D | 1 |
| Barr, IG; Holien, JK; Hurt, AC; Kelso, A; Parker, M | 1 |
| Hacker, J | 1 |
| Bailey, KW; Furuta, Y; Hurst, BL; Morrey, JD; Smee, DF; Tarbet, EB; Wong, MH | 1 |
| Brakenhoff, JP; Cornelissen, LA; Friesen, RH; Goudsmit, J; Koldijk, MH; Koudstaal, W; Weverling, GJ | 1 |
| Kakuta, M; Kubo, S; Tokumitsu, A; Tomozawa, T; Yamashita, M | 2 |
| Abed, Y; Baz, M; Boivin, G; Hamelin, ME; Simon, P | 1 |
| Kawaoka, Y; Kiso, M; Kubo, S; Le, QM; Nidom, CA; Ozawa, M; Yamashita, M | 1 |
| Chida, J; Fujihashi, K; Fujii, K; Fukui, M; Kataoka, K; Kido, H; Mizuno, D; Takahashi, E | 1 |
| Govorkova, EA; Ilyushina, NA; Marathe, BM; McClaren, JL; Webster, RG | 2 |
| Govorkova, EA; Ilyushina, NA; Rehg, JE; Seiler, JP; Webster, RG | 1 |
| Barr, IG; Hurt, AC; Lowther, S; Middleton, D | 1 |
| Babu, YS; Hurst, BL; Klumpp, K; Morrey, JD; Smee, DF; Tarbet, EB; Wong, MH | 1 |
| DeLiberto, T; DuBois, RM; Govorkova, EA; Gramer, MR; Krauss, S; Negovetich, NJ; Senne, DA; Stallknecht, DE; Stoner, TD; Swafford, S; Webster, RG | 1 |
| Lau, YF; Ooi, EE; Subbarao, K; Tang, LH | 1 |
| Boltz, DA; Bragstad, K; Duan, S; Govorkova, EA; Li, J; Nielsen, LP; Seiler, P; Webby, RJ; Webster, RG | 2 |
| Albrecht, RA; García-Sastre, A; Kaminski, M; Kochs, G; Medina, RA; Palese, P; Philipp, J; Rubbenstroth, D; Schwalm, F; Seibert, CW; Staeheli, P; Stertz, S | 1 |
| Chang, KO; Kim, Y; Narayanan, S | 1 |
| Chuman, H; Harada, M; Hitaoka, S; Yoshida, T | 1 |
| Furuta, Y; Kakugawa, S; Katsura, H; Kawaoka, Y; Kiso, M; Le, MT; Ozawa, M; Shimojima, M; Shinya, K; Takahashi, K; Takano, R; Yamashita, M | 1 |
| Dubielzig, RR; Hatta, M; Hatta, Y; Hershberger, K; Katze, MG; Kawaoka, Y; Proll, SC; Shinya, K; Suresh, M | 1 |
| Agafonov, AP; Demina, OK; Drozdov, IG; Erdyneeva, UB; Kabanov, AS; Nebol'sin, VE; Sergeev, AA; Serova, OA; Shishkina, LN; Skarnovich, MO; Stavskiĭ, EA | 1 |
| Bondarev, VP; Borisevich, SV; Loginova, SIa; Maksimov, VA; Nebol'sin, VE; Shkliaeva, OM | 1 |
| Belopolskaya, MV; Drozdov, IG; Epstein, OI; Kabanov, AS; Malkova, EM; Olkin, SE; Sergeev, AA; Sergeeva, SA; Shishkina, LN; Skarnovich, MO; Stavsky, EA; Tarasov, SA | 1 |
| Horimoto, T; Imai, H; Kakugawa, S; Kawaoka, Y; Kiso, M; Le, MT; Noda, T; Ozawa, M; Takahashi, K | 1 |
| Yoo, ES | 1 |
| Govorkova, EA; Marathe, BM; Prevost, A; Rehg, JE; Webster, RG | 1 |
| Bauer, K; Dahse, HM; Dürrwald, R; Pfarr, K; Schlegel, M; Schmidtke, M; Topf, D; Wiesener, N; Wutzler, P | 1 |
| Das, SC; Fremgen, DM; Hatta, M; Jatzek, A; Kawaoka, Y; Oldstone, MB; Rosen, H; Shinya, K; Suresh, M; Teijaro, JR; Walsh, KB; Watanabe, T; Wilker, PR | 1 |
| Birge, M; Carbain, B; Martin, SR; Stanley, M; Streicher, H | 1 |
| Choi, HJ; Kwon, DH; Song, JH | 1 |
| Hurst, BL; Smee, DF; Wong, MH | 1 |
| Jin, M; Li, B; Wang, G; Wang, X; Wu, H | 1 |
| Baz, M; Beaulieu, E; Boivin, G; Bouhy, X; Dubé, K; Hamelin, ME; Mallett, C | 1 |
| Barnard, DL; Dagley, A; Hagloch, J; Julander, JG; Latimer, S; Morrey, JD; Motter, N; Smee, DF | 1 |
| Bröjer, C; Fick, J; Grabic, R; Gunnarsson, G; Järhult, JD; Latorre-Margalef, N; Lennerstrand, J; Lundkvist, A; Muradrasoli, S; Olsen, B; Orozovic, G; Söderström, H; Wahlgren, J; Waldenström, J | 1 |
| Chan, KH; Chen, H; Chen, Y; Lau, SY; Lin, T; Mok, BW; Song, W; Wang, G; Wang, P; Wen, X; Wu, WL; Yuen, KY | 1 |
| Haruyama, T; Mori, K; Nagata, K | 1 |
| Beck, MA | 1 |
| Duan, S; Govorkova, EA; McCullers, JA; O'Brien, KB; Schultz-Cherry, S; Vogel, P; Webby, RJ | 1 |
| Belser, JA; Gubareva, LV; Katz, JM; Pearce, MB; Sleeman, K; Tumpey, TM | 1 |
| Abed, Y; Beaulieu, E; Boivin, G; Bouhy, X; Mallett, C; Pizzorno, A; Russell, R | 1 |
| Jurkuvenaite, A; Matalon, S; Noah, DL; Noah, JW; Steele, C; Zarogiannis, SG | 1 |
| Böhm, R; Dyason, JC; Garcia, JM; Haselhorst, T; Lai, JC; Madge, PD; Nicholls, JM; Peiris, JS; Rose, FJ; von Itzstein, M | 1 |
| Barnard, DL; de Jong, MD; Gross, M; Julander, JG; Nguyen, JT; Smee, DF; Went, GT | 1 |
| Bouvier, NM; Krammer, F; Palese, P; Rahmat, S; Seibert, CW | 1 |
| Bouvier, NM; Pica, N; Rahmat, S | 1 |
| Galabov, AS; Gegova, G; Simeonova, L | 2 |
| Abed, Y; Boivin, G; Pizzorno, A | 1 |
| Bestebroer, TM; Burke, DF; Chutinimitkul, S; de Wit, E; Fouchier, RA; Herfst, S; Linster, M; Munster, VJ; Osterhaus, AD; Rimmelzwaan, GF; Schrauwen, EJ; Smith, DJ; Sorrell, EM | 1 |
| Feng, E; Hilgenfeld, R; Jiang, H; Li, J; Liu, H; Wang, J; Ye, D; Zhang, D; Zhao, F; Zheng, M | 1 |
| Gross, M; Julander, JG; Nguyen, J; Smee, DF; Tarbet, EB | 1 |
| Chida, J; Fujihashi, K; Fujii, K; Indalao, IL; Kataoka, K; Kido, H; Konoha, K; Mizuno, D; Takahashi, E | 1 |
| Carroll, MW; Cheung, L; Dimmock, NJ; Dove, BK; Easton, AJ; Hallis, B; Marriott, AC; Meng, B; Scott, PD; Taylor, I | 1 |
| Igarashi, M; Ito, K; Kawaoka, Y; Kiso, M; Le, QM; Sekijima, M; Takada, A; Takano, R | 1 |
| Oldstone, MB; Rosen, H; Teijaro, JR; Walsh, KB | 1 |
| Hayashi, K; Hayashi, T; Lee, JB; Nakano, T | 1 |
| Bartmess, KC; McCullers, JA | 1 |
| Enserink, M | 2 |
| Blanco, J; Curtis, S; Ottolini, M; Peterson, L; Porter, D; Prince, G | 1 |
| Gondo, H; Harada, M; Iino, T; Ito, H; Miyamoto, T; Nagafuji, K; Nozoe, M | 1 |
| Egawa, H; Fukuda, Y; Furuta, Y; Kamiyama, T; Kozaki, K; Kuno, M; Minami, S; Nomura, N; Shiraki, K; Takahashi, K | 1 |
| McCullers, JA | 1 |
| Elias, S; Herlocher, ML; Monto, AS; Ohmit, SE; Roberts, NA; Truscon, R; Yen, HL | 1 |
| Bailey, KW; Sidwell, RW; Smee, DF; Wandersee, MK; Wong, MH | 1 |
| Babu, YS; Bantia, S; Chand, P; El-Kattan, Y; Kotian, PL; Lin, TH | 1 |
| Govorkova, EA; Monto, AS; Webster, RG; Yen, HL | 1 |
| Govorkova, EA; Herlocher, LM; Hoffmann, E; Matrosovich, MN; Monto, AS; Webster, RG; Yen, HL | 1 |
| Braciale, TJ; Gubareva, LV; Hayden, FG; Ison, MG; Mishin, VP | 1 |
| Hobo, S; Kondo, T; Matsumura, T; Tsujimura, K; Yamanaka, T | 1 |
| Bailey, KW; Sidwell, RW; Smee, DF; Wong, MH | 1 |
| Fauci, AS | 1 |
| Hobo, S; Kondo, T; Kurosawa, M; Matsumura, T; Nagata, S; Tsujimura, K; Yamada, M; Yamanaka, T | 1 |
| Govorkova, EA; Hoffmann, E; Ilyushina, NA; Salomon, R; Webster, RG | 1 |
| Finsterbusch, T; Hengel, H; Masihi, KN; Schweiger, B | 1 |
| Reece, PA | 1 |
| Arnold, CS; Barr, IG; Dziuba, N; Holbrook, MR; Hurt, AC; Kilpatrick, JM; Linde, NS; Paessler, S; Smith, JN; Yun, NE; Zacks, MA; Zhang, L | 1 |
| Boltz, DA; Govorkova, EA; McClaren, J; Rehg, JE; Webster, RG | 1 |
| Bischofberger, N; Chen, MS; Escarpe, PA; Huffman, JH; Jakeman, KJ; Kim, CU; Lacy, SA; Lew, W; Li, W; Mendel, DB; Merson, J; Sidwell, RW; Sweet, C; Tai, CY; Williams, MA; Zhang, L | 1 |
| Bischofberger, N; Chen, MS; Cundy, KC; Eisenberg, EJ; Escarpe, PA; Jakeman, KJ; Kim, CU; Lew, W; Li, W; Mendel, DB; Merson, J; Sweet, C; Williams, M; Zhang, L | 1 |
| Bailey, KW; Billingsley, JL; Burger, RA; Huffman, JH; Kim, CU; Sidwell, RW | 1 |
| Babu, YS; Bailey, KW; Barnard, DL; Huffman, JH; Morrey, JD; Sidwell, RW; Smee, DF | 1 |
| Ananth, SL; Andries, K; Babu, YS; Bantia, S; Chand, P; Dehghani, A; El-Kattan, Y; Horn, LL; Hutchison, TL; Kellog, DL; Kotian, PL; Lin, T; Montgomery, JA; Parker, CD | 1 |
| Bush, K; Goloubeva, OG; Govorkova, EA; Leneva, IA; Webster, RG | 1 |
| Babu, YS; Bush, K; Chand, P; Desai-Krieger, D; Jakeman, KJ; McKown, LA; Streeter, AJ; Sweet, C; Wagaman, PC | 1 |
| Bailey, KW; Barnard, DL; Jackson, MK; Sidwell, RW; Smee, DF; Wong, MH | 1 |
7 review(s) available for oseltamivir and Orthomyxoviridae Infections
| Article | Year |
|---|---|
Oseltamivir analogs with potent anti-influenza virus activity.
Topics: Animals; Antiviral Agents; Humans; Life Cycle Stages; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir | 2020 |
Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Enzyme Inhibitors; Hemagglutinins, Viral; Humans; Influenza, Human; Mice; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Viral Envelope Proteins | 2021 |
Oseltamivir for treatment and prophylaxis of influenza infection.
Topics: Animals; Antiviral Agents; Humans; Influenza, Human; Orthomyxoviridae Infections; Oseltamivir | 2009 |
Study of specific oligosaccharide structures related with swine flu (H1N1) and avian flu, and tamiflu as their remedy.
Topics: Animals; Birds; Humans; Influenza A Virus, H1N1 Subtype; Influenza in Birds; Influenza, Human; Oligosaccharides; Orthomyxoviridae Infections; Oseltamivir | 2011 |
Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Benzoic Acid; Cyclopentanes; Drug Design; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Models, Molecular; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2012 |
Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection.
Topics: Animals; Cytokines; Drug Synergism; Drug Therapy, Combination; Endothelial Cells; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung; Mice; Mycotoxins; Orthomyxoviridae Infections; Oseltamivir; Receptors, Lysosphingolipid; Survival Rate | 2013 |
Neuraminidase inhibitor resistance in influenza viruses.
Topics: Acids, Carbocyclic; Adult; Animals; Antiviral Agents; Catalytic Domain; Child; Clinical Trials as Topic; Cyclopentanes; Drug Administration Schedule; Enzyme Inhibitors; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Seasons; Sentinel Surveillance; Viral Proteins; Virulence; Zanamivir | 2007 |
2 trial(s) available for oseltamivir and Orthomyxoviridae Infections
| Article | Year |
|---|---|
Results from a test-and-treat study for influenza among residents of homeless shelters in King County, WA: A stepped-wedge cluster-randomized trial.
Topics: Antiviral Agents; Humans; Ill-Housed Persons; Influenza A Virus, H1N1 Subtype; Influenza, Human; Orthomyxoviridae Infections; Oseltamivir | 2023 |
Efficacy of oseltamivir phosphate to horses inoculated with equine influenza A virus.
Topics: Acetamides; Animals; Bronchoalveolar Lavage Fluid; Female; Fever; Horse Diseases; Horses; Influenza A Virus, H3N8 Subtype; Lung; Male; Orthomyxoviridae Infections; Oseltamivir; Time Factors | 2006 |
206 other study(ies) available for oseltamivir and Orthomyxoviridae Infections
| Article | Year |
|---|---|
Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Ferrets; Influenza A Virus, H5N1 Subtype; Orthomyxoviridae Infections; Oseltamivir | 2007 |
Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice.
Topics: Animals; Drug Resistance, Fungal; Influenza A Virus, H1N1 Subtype; Lung; Mice; Mice, Inbred BALB C; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrrolidines; Reverse Transcriptase Polymerase Chain Reaction; Viral Load | 2009 |
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Influenza A Virus, H5N1 Subtype; Mutagenesis, Site-Directed; Mutation; Neuraminidase; Orthomyxoviridae Infections; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Development of oseltamivir phosphonate congeners as anti-influenza agents.
Topics: Acetamides; Administration, Oral; Alphainfluenzavirus; Animals; Antiviral Agents; Betainfluenzavirus; Biological Availability; Blood Proteins; Cyclohexenes; Cytopathogenic Effect, Viral; Dogs; Drug Resistance, Viral; Drug Stability; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Madin Darby Canine Kidney Cells; Male; Mice; Mice, Inbred BALB C; Microsomes, Liver; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Phosphorous Acids; Protein Binding; Rats; Structure-Activity Relationship | 2012 |
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.
Topics: Administration, Oral; Animals; Antiviral Agents; Aza Compounds; Biological Availability; Dogs; Drug Resistance, Viral; Indoles; Influenza A virus; Madin Darby Canine Kidney Cells; Male; Mice, Inbred BALB C; Models, Molecular; Molecular Structure; Orthomyxoviridae Infections; Rats; RNA-Dependent RNA Polymerase; Species Specificity; Stereoisomerism; Structure-Activity Relationship; Viral Proteins; Virus Replication | 2014 |
Boronic Acid Modifications Enhance the Anti-Influenza A Virus Activities of Novel Quindoline Derivatives.
Topics: Alkaloids; Animals; Antiviral Agents; Boronic Acids; Cell Line; Female; Humans; Indoles; Influenza A virus; Influenza, Human; Mice; NF-kappa B; Orthomyxoviridae Infections; Quinolines; Signal Transduction | 2017 |
Synthesis, structure activity relationship and in vitro anti-influenza virus activity of novel polyphenol-pentacyclic triterpene conjugates.
Topics: Animals; Antiviral Agents; Dogs; Hemagglutination; Humans; Influenza A Virus, H1N1 Subtype; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Models, Molecular; Orthomyxoviridae Infections; Pentacyclic Triterpenes; Polyphenols; Structure-Activity Relationship; Virus Internalization | 2019 |
Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection.
Topics: A549 Cells; Animals; Antiviral Agents; Chemokines; Cytokines; Dibenzothiepins; Drug Therapy, Combination; Female; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Lung; Mice; Mice, Inbred BALB C; Morpholines; Orthomyxoviridae Infections; Oseltamivir; Pneumonia; Pyridones; Sequence Analysis; Triazines; Virus Replication | 2022 |
Forsythiaside A improves Influenza A virus infection through TLR7 signaling pathway in the lungs of mice.
Topics: Animals; Glycosides; Influenza A Virus, H1N1 Subtype; Lung; Mice; Orthomyxoviridae Infections; Oseltamivir; Signal Transduction; Toll-Like Receptor 7 | 2022 |
The induction of virus-neutralizing antibodies in influenza A-infected mice treated with Oseltamivir phosphate: effect of dosage and scheduling.
Topics: Animals; Antibodies, Neutralizing; Antiviral Agents; Humans; Influenza A virus; Influenza, Human; Lung; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Phosphates | 2022 |
MicroRNA-205-5p: A potential therapeutic target for influenza A.
Topics: Animals; Binding Sites; Influenza A virus; Mice; MicroRNAs; Orthomyxoviridae Infections; Oseltamivir | 2022 |
Death in children with influenza A (H3N2) virus infection-associated encephalopathy: two case reports.
Topics: Brain Diseases; Child; Encephalitis; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Orthomyxoviridae Infections; Oseltamivir | 2023 |
Exploration of the mechanisms of Ge Gen Decoction against influenza A virus infection.
Topics: Animals; Antiviral Agents; Cytokines; Dogs; Drugs, Chinese Herbal; Female; Influenza A virus; Influenza A Virus, H1N1 Subtype; Lung; Madin Darby Canine Kidney Cells; Membrane Glycoproteins; Mice, Inbred ICR; Orthomyxoviridae Infections; Oseltamivir; Signal Transduction; Th1-Th2 Balance; Toll-Like Receptor 7; Virus Attachment; Virus Replication | 2019 |
Oseltamivir Is Effective against 1918 Influenza Virus Infection of Macaques but Vulnerable to Escape.
Topics: Animals; Influenza A Virus, H1N1 Subtype; Macaca; Orthomyxoviridae Infections; Oseltamivir | 2019 |
Gegen Qinlian Decoction Downregulates the TLR7 Signalling Pathway to Control Influenza A Virus Infection.
Topics: Animals; Antiviral Agents; Down-Regulation; Drugs, Chinese Herbal; Female; Influenza A virus; Male; Medicine, Chinese Traditional; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Myeloid Differentiation Factor 88; NF-kappa B; Orthomyxoviridae Infections; Oseltamivir; Signal Transduction; T-Lymphocytes; Toll-Like Receptor 7 | 2020 |
Unique synergistic antiviral effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease.
Topics: Acute Lung Injury; Animals; Antiviral Agents; Bronchi; Bronchoalveolar Lavage Fluid; Cell Line; Coculture Techniques; Drugs, Chinese Herbal; Epithelial Cells; Humans; Inflammasomes; Inflammation; Influenza A virus; Influenza, Human; Interleukin-18; Interleukin-1beta; Lung; Male; Orthomyxoviridae Infections; Oseltamivir; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Viral Load | 2020 |
Early Administration of Oseltamivir Within 48 Hours After Onset of Flulike Symptoms Can Reduce the Risk of Influenza B Virus-Associated Pneumonia in Hospitalized Pediatric Patients with Influenza B Virus Infection.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza B virus; Male; Orthomyxoviridae Infections; Oseltamivir; Pneumonia, Viral; Post-Exposure Prophylaxis; Retrospective Studies; Time-to-Treatment; Treatment Outcome | 2020 |
Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy.
Topics: Administration, Oral; Animals; Antiviral Agents; Chemoprevention; Dogs; Drug Combinations; Drug Resistance, Viral; Female; Ferrets; Influenza A Virus, H1N1 Subtype; Lung; Madin Darby Canine Kidney Cells; Male; Nitro Compounds; Orthomyxoviridae Infections; Oseltamivir; Thiazoles; Virus Shedding | 2020 |
Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2020 |
The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets.
Topics: Animals; Antiviral Agents; Body Temperature; Dibenzothiepins; Ferrets; Humans; Influenza A virus; Influenza, Human; Microsomes; Morpholines; Orthomyxoviridae Infections; Oseltamivir; Pyridones; Triazines; Viral Load | 2020 |
Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir.
Topics: Animals; Antiviral Agents; Cell Proliferation; Dogs; Drug Resistance, Viral; Drug Therapy, Combination; Female; Ferrets; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Male; Nitro Compounds; Orthomyxoviridae Infections; Oseltamivir; Thiazoles | 2020 |
Utilising animal models to evaluate oseltamivir efficacy against influenza A and B viruses with reduced in vitro susceptibility.
Topics: Amino Acid Substitution; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Ferrets; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Macaca fascicularis; Macrolides; Male; Mutation, Missense; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir | 2020 |
Viral burden, inflammatory milieu and CD8
Topics: Animals; Antiviral Agents; Bronchoalveolar Lavage Fluid; CD8-Positive T-Lymphocytes; Cytokines; Inflammation; Influenza A virus; Killer Cells, Natural; Lung; Mice; Neutrophils; Orthomyxoviridae Infections; Oseltamivir; Thiazoles; Viral Load; Weight Loss | 2020 |
Battling COVID-19 Pandemic: Sphingosine-1-Phosphate Analogs as an Adjunctive Therapy?
Topics: Animals; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Humans; Indans; Influenza A Virus, H1N1 Subtype; Lysophospholipids; Mice; Orthomyxoviridae Infections; Oseltamivir; Oxadiazoles; Pandemics; Pneumonia, Viral; SARS-CoV-2; Sphingosine; Sphingosine-1-Phosphate Receptors | 2020 |
Differential Viral-Host Immune Interactions Associated with Oseltamivir-Resistant H275Y and Wild-Type H1N1 A(pdm09) Influenza Virus Pathogenicity.
Topics: Animals; Antiviral Agents; Dogs; Drug Resistance, Viral; Female; Ferrets; Genetic Fitness; Host Microbial Interactions; Influenza A Virus, H1N1 Subtype; Lung; Madin Darby Canine Kidney Cells; Male; Mice; Mice, Inbred C57BL; Mutation, Missense; Orthomyxoviridae Infections; Oseltamivir; Virulence; Virus Replication | 2020 |
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Topics: Animals; Antiviral Agents; Betacoronavirus; Binding Sites; Cell Line; Coronavirus Infections; COVID-19; Crotonates; Cytokine Release Syndrome; Dihydroorotate Dehydrogenase; Drug Evaluation, Preclinical; Gene Knockout Techniques; Humans; Hydroxybutyrates; Influenza A virus; Leflunomide; Mice; Mice, Inbred BALB C; Nitriles; Orthomyxoviridae Infections; Oseltamivir; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Pandemics; Pneumonia, Viral; Protein Binding; Pyrimidines; RNA Viruses; SARS-CoV-2; Structure-Activity Relationship; Thiazoles; Toluidines; Ubiquinone; Virus Replication | 2020 |
Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase.
Topics: Animals; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dihydroorotate Dehydrogenase; Drug Discovery; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Mice; Molecular Structure; Orthomyxoviridae Infections; Oseltamivir; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Pandemics; Pneumonia, Viral; Pyrimidines; SARS-CoV-2 | 2020 |
In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; Cell Line; Dibenzothiepins; Dogs; Drug Combinations; Drug Resistance, Viral; Drug Synergism; Guanidines; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Morpholines; Neuraminidase; Nucleic Acid Synthesis Inhibitors; Orthomyxoviridae Infections; Oseltamivir; Pyrazines; Pyridones; Ribavirin; Triazines; Viral Proteins; Virus Replication; Zanamivir | 2020 |
Administration of a CXC Chemokine Receptor 2 (CXCR2) Antagonist, SCH527123, Together with Oseltamivir Suppresses NETosis and Protects Mice from Lethal Influenza and Piglets from Swine-Influenza Infection.
Topics: Animals; Benzamides; Cyclobutanes; Extracellular Traps; Humans; Influenza, Human; Leukocyte Elastase; Lung; Mice; Neutrophil Activation; Neutrophils; Orthomyxoviridae Infections; Oseltamivir; Receptors, Interleukin-8B; Swine | 2021 |
An influenza A(H5N8) virus isolated during an outbreak at a poultry farm in Russia in 2017 has an N294S substitution in the neuraminidase and shows reduced susceptibility to oseltamivir.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Farms; Genetic Markers; Influenza A Virus, H5N8 Subtype; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Poultry; Russia; Viral Proteins | 2021 |
Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in influenza A virus PA gene in a mouse model.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Dibenzothiepins; Disease Models, Animal; Drug Resistance, Viral; Influenza A Virus, H1N1 Subtype; Mice; Morpholines; Orthomyxoviridae Infections; Oseltamivir; Pyridones; Triazines; Viral Load | 2021 |
Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Birds; Cell Line; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Female; HEK293 Cells; Humans; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred C57BL; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Viral Proteins; Virus Replication | 2021 |
Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with
Topics: Animals; Antibodies, Viral; Antiviral Agents; Deuterium; Dogs; Drug Resistance, Viral; Humans; Influenza A virus; Madin Darby Canine Kidney Cells; Male; Mice, Inbred BALB C; Mutation; Orthomyxoviridae Infections; Oseltamivir; Structure-Activity Relationship; Viral Matrix Proteins; Viroporin Proteins | 2021 |
Combinations of L-N
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Synergism; Enzyme Inhibitors; Female; Influenza A Virus, H1N1 Subtype; Mice; Mice, Inbred BALB C; omega-N-Methylarginine; Orthomyxoviridae Infections; Oseltamivir | 2017 |
The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antibodies, Viral; Antibody Specificity; Antiviral Agents; Female; Ferrets; Humans; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir | 2017 |
Rapamycin adjuvant and exacerbation of severe influenza in an experimental mouse model.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Disease Progression; Immunity, Cellular; Influenza A virus; Lung; Mice; Mice, Transgenic; Orthomyxoviridae Infections; Oseltamivir; Severity of Illness Index; Sirolimus; T-Lymphocytes | 2017 |
Antiviral activity of a synthesized shikonin ester against influenza A (H1N1) virus and insights into its mechanism.
Topics: A549 Cells; Animals; Antiviral Agents; Apoptosis; Cell Line; Cell Line, Tumor; Dogs; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Naphthoquinones; Orthomyxoviridae Infections; Oseltamivir; Structure-Activity Relationship; Viral Proteins | 2017 |
The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus.
Topics: Animals; Antiviral Agents; Azithromycin; Drug Therapy, Combination; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Injections, Intraperitoneal; Lung; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Viral Load | 2017 |
The Combined Effect of Oseltamivir and Favipiravir on Influenza A Virus Evolution.
Topics: Amides; Animals; Antiviral Agents; Biological Evolution; Cell Line; Dogs; Genetics, Population; Influenza A virus; Mutation Rate; Orthomyxoviridae Infections; Oseltamivir; Pyrazines | 2017 |
Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques.
Topics: Animals; Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Viral; Female; Hemagglutinin Glycoproteins, Influenza Virus; High-Throughput Nucleotide Sequencing; Immunocompromised Host; Influenza A Virus, H7N9 Subtype; Macaca fascicularis; Male; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Virus Replication | 2017 |
Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection.
Topics: Animals; Antiviral Agents; Chemokine CXCL10; Chick Embryo; Dogs; Female; Gene Expression Regulation; Host-Pathogen Interactions; Immunologic Factors; IMP Dehydrogenase; Influenza A Virus, H5N1 Subtype; Interferon-beta; Interleukin-1beta; Interleukin-6; Lung; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Mycophenolic Acid; Orthomyxoviridae Infections; Oseltamivir; RNA, Viral; Survival Analysis; Virus Replication; Zanamivir | 2017 |
A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses.
Topics: Animals; Antibodies, Neutralizing; Antibodies, Viral; Binding Sites; Cross Protection; Dogs; Drug Therapy, Combination; Epitope Mapping; Epitopes; Female; Ferrets; Hemagglutinin Glycoproteins, Influenza Virus; Immunization; Influenza B virus; Madin Darby Canine Kidney Cells; Mice, Inbred BALB C; Models, Molecular; Orthomyxoviridae Infections; Oseltamivir; Protein Domains; Receptors, Virus; Treatment Outcome | 2017 |
A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment.
Topics: Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Dogs; Humans; Immunocompromised Host; Influenza B virus; Lung; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Treatment Outcome; Viral Load; Virulence; Virus Replication | 2017 |
Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus.
Topics: Amides; Animals; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Female; Guanidines; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Lung; Mice; Mice, Inbred BALB C; Mice, Nude; Neuraminidase; Nucleic Acid Synthesis Inhibitors; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Pyrazines; Sialic Acids; Zanamivir | 2018 |
Combined efficacy of oseltamivir, isoprinosine and ellagic acid in influenza A(H3N2)-infected mice.
Topics: Animals; Antioxidants; Antiviral Agents; Cell Line; Dogs; Drug Therapy, Combination; Ellagic Acid; Influenza A Virus, H3N2 Subtype; Inosine Pranobex; Lung; Madin Darby Canine Kidney Cells; Male; Mice; Mice, Inbred ICR; Orthomyxoviridae Infections; Oseltamivir; Oxidation-Reduction; Oxidative Stress; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2018 |
The effect of P38 MAP kinase inhibition in a mouse model of influenza.
Topics: Animals; Antiviral Agents; Bronchi; Cell Line; Cytokines; Dexamethasone; Disease Models, Animal; Enzyme Inhibitors; Epithelial Cells; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; p38 Mitogen-Activated Protein Kinases; Treatment Outcome; Virus Replication | 2018 |
Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Multiple, Viral; Female; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Mice, Inbred BALB C; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Viral Proteins | 2018 |
Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Endosomes; Gene Expression Regulation, Neoplastic; Influenza A virus; Mice; Nucleocapsid Proteins; Orthomyxoviridae Infections; Oseltamivir; Protein Transport; Pyrans; RNA-Binding Proteins; Viral Core Proteins; Viral Matrix Proteins; Virus Internalization | 2018 |
Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus.
Topics: Amides; Animals; Antiviral Agents; Cytokines; Disease Models, Animal; Drug Resistance, Viral; Drug Therapy, Combination; Female; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Mice; Orthomyxoviridae Infections; Oseltamivir; Pyrazines | 2018 |
Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.
Topics: Administration, Oral; Animals; Antiviral Agents; Dibenzothiepins; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Influenza A virus; Mice, Inbred BALB C; Morpholines; Orthomyxoviridae Infections; Oseltamivir; Oxazines; Pyridines; Pyridones; Survival Analysis; Thiepins; Treatment Outcome; Triazines; United States | 2019 |
Untargeted metabolomics analysis of the upper respiratory tract of ferrets following influenza A virus infection and oseltamivir treatment.
Topics: Animals; Antiviral Agents; Ferrets; Gas Chromatography-Mass Spectrometry; Influenza A virus; Metabolomics; Orthomyxoviridae Infections; Oseltamivir; Respiratory System; Respiratory Tract Infections | 2019 |
Combination of sphingosine-1-phosphate receptor 1 (S1PR1) agonist and antiviral drug: a potential therapy against pathogenic influenza virus.
Topics: Administration, Intranasal; Animals; Antiviral Agents; Blotting, Western; Female; Fluorescent Antibody Technique; Indans; Influenza A Virus, H1N1 Subtype; Lung; Male; Mice; Mice, Knockout; Orthomyxoviridae Infections; Oseltamivir; Oxadiazoles; Real-Time Polymerase Chain Reaction; Sphingosine-1-Phosphate Receptors | 2019 |
Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Enzyme Inhibitors; Female; Guanidines; Inflammation; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2019 |
Combination Therapy Targeting Platelet Activation and Virus Replication Protects Mice against Lethal Influenza Pneumonia.
Topics: Animals; Clopidogrel; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Extracellular Traps; Female; Histones; Influenza A Virus, H1N1 Subtype; Lung; Mice; Neutrophils; Orthomyxoviridae Infections; Oseltamivir; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Pneumonia, Viral; Thrombophilia; Virus Replication | 2019 |
Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir.
Topics: Animals; Antiviral Agents; Flagellin; Influenza A virus; Interferon Type I; Interleukin-22; Interleukins; Lung; Mice; Mice, Inbred C57BL; Mice, Knockout; Orthomyxoviridae Infections; Oseltamivir; Toll-Like Receptor 5; Virus Replication | 2019 |
Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models.
Topics: Administration, Oral; Animals; Antiviral Agents; Dibenzothiepins; Disease Models, Animal; Drug Administration Schedule; Enzyme Inhibitors; Female; Host Microbial Interactions; Humans; Immunocompetence; Immunocompromised Host; Influenza A virus; Influenza B virus; Influenza, Human; Mice; Mice, Inbred BALB C; Morpholines; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Oxazines; Pyridines; Pyridones; Thiepins; Triazines; Virus Replication | 2019 |
Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Lung; Mice; Orthomyxoviridae Infections; Oseltamivir; Simvastatin; Survival Analysis; Treatment Outcome; Viral Load | 2013 |
Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Body Weight; Cyclopentanes; Cyclophosphamide; Drug Administration Schedule; Female; Guanidines; Immunosuppressive Agents; Influenza A Virus, H1N1 Subtype; Injections, Intravenous; Lung; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Phosphorous Acids; Survival Analysis; Treatment Outcome | 2013 |
Immunomodulaton and attenuation of lethal influenza A virus infection by oral administration with KIOM-C.
Topics: Administration, Oral; Angelica; Animals; Antiviral Agents; Bronchoalveolar Lavage Fluid; Cytokines; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ferrets; Glycyrrhiza; Immunologic Factors; Immunomodulation; Influenza A Virus, H1N1 Subtype; Lung; Madin Darby Canine Kidney Cells; Mice; Orthomyxoviridae Infections; Oseltamivir; Phytotherapy; Plant Extracts; Scutellaria baicalensis; Survival Analysis; Viral Load; Viral Plaque Assay; Virus Replication | 2013 |
Efficacy of influenza vaccination and tamiflu® treatment--comparative studies with Eurasian Swine influenza viruses in pigs.
Topics: Animals; Antibodies, Viral; Antiviral Agents; Female; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H1N2 Subtype; Influenza Vaccines; Male; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Sus scrofa; Swine; Swine Diseases; Vaccination; Viral Proteins; Virus Replication | 2013 |
Antigen-activated dendritic cells ameliorate influenza A infections.
Topics: Animals; Antigens, Viral; Antiviral Agents; CD8-Positive T-Lymphocytes; Cells, Cultured; Combined Modality Therapy; Dendritic Cells; Drug Resistance, Viral; Female; Humans; Immunotherapy; Influenza A Virus, H1N1 Subtype; Lung; Male; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Peptide Fragments; Viral Load; Virus Replication; Weight Loss | 2013 |
Combined administration of oseltamivir and hochu-ekki-to (TJ-41) dramatically decreases the viral load in lungs of senescence-accelerated mice during influenza virus infection.
Topics: Administration, Oral; Aging; Animals; Antiviral Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Drugs, Chinese Herbal; Immunologic Factors; Influenza A virus; Lung; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Orthomyxoviridae Infections; Oseltamivir; Treatment Outcome; Viral Load | 2014 |
Aronia melanocarpa and its components demonstrate antiviral activity against influenza viruses.
Topics: Animals; Antiviral Agents; Cell Line; Drug Resistance, Viral; Ellagic Acid; Female; Flavonoids; Fruit; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza, Human; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Photinia; Plant Extracts; Polyphenols; Virus Replication | 2013 |
Antigenicity and transmissibility of a novel clade 2.3.2.1 avian influenza H5N1 virus.
Topics: Animals; Antiviral Agents; Birds; Cell Line; Ferrets; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Molecular Sequence Data; Orthomyxoviridae Infections; Oseltamivir; Phylogeny; Sequence Analysis, DNA | 2013 |
Germacrone inhibits early stages of influenza virus infection.
Topics: Animals; Antiviral Agents; Cell Line; Chick Embryo; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Lung; Madin Darby Canine Kidney Cells; Mice; Orthomyxoviridae Infections; Oseltamivir; Phytotherapy; Ribavirin; Sesquiterpenes, Germacrane; Specific Pathogen-Free Organisms; Virus Attachment; Virus Cultivation; Virus Replication | 2013 |
The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice.
Topics: Acids, Carbocyclic; Administration, Intravenous; Administration, Oral; Animals; Antiviral Agents; Chemokine CXCL2; Chemokines; Coinfection; Cyclopentanes; Guanidines; Influenza A Virus, H1N1 Subtype; Interferon-gamma; Interleukin-6; Lung; Male; Mice; Mice, Inbred CBA; Orthomyxoviridae Infections; Oseltamivir; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Survival Analysis; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses.
Topics: Animals; Antiviral Agents; Body Weight; Disease Models, Animal; Drug Therapy, Combination; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Lung; Mice, Inbred C57BL; Orthomyxoviridae Infections; Oseltamivir; Survival Analysis; Treatment Outcome; Viral Load; Zanamivir | 2014 |
Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Ferrets; Influenza A Virus, H1N1 Subtype; Orthomyxoviridae Infections; Oseltamivir; Treatment Outcome; Virus Shedding | 2014 |
A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.
Topics: Animals; Antiviral Agents; Dogs; Drug Combinations; Drug Resistance, Viral; Enzyme Inhibitors; Female; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2014 |
The combination of ribavirin and ozeltamivir effectively inhibits reproduction of influenza A virus resistant to rimantadine (amantadine) in vitro and in vivo.
Topics: Amantadine; Animals; Antiviral Agents; Dogs; Drug Combinations; Drug Resistance, Viral; Influenza A virus; Madin Darby Canine Kidney Cells; Mice; Orthomyxoviridae Infections; Oseltamivir; Ribavirin; Virus Replication | 2014 |
Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.
Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; Body Weight; Cyclopentanes; Dogs; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Female; Guanidines; Influenza A Virus, H1N1 Subtype; Lung; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred DBA; Orthomyxoviridae Infections; Oseltamivir; Pyrazines; Survival Rate | 2014 |
Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.
Topics: Animals; Antiviral Agents; Base Sequence; Cell Line; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Evolution, Molecular; Hemagglutinins, Viral; High-Throughput Nucleotide Sequencing; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Recombinant Proteins; Selection, Genetic; Sequence Analysis, RNA; Viral Proteins | 2014 |
Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mutant Proteins; Mutation, Missense; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Viral Proteins; Virus Cultivation; Virus Replication | 2015 |
Aging exacerbates damage and delays repair of alveolar epithelia following influenza viral pneumonia.
Topics: Age Factors; Aging; Alveolar Epithelial Cells; Animals; Antiviral Agents; Cell Proliferation; Disease Models, Animal; Female; Influenza A Virus, H1N1 Subtype; Mice, Inbred C57BL; Orthomyxoviridae Infections; Oseltamivir; Pneumonia, Viral; Pulmonary Alveoli; Regeneration; Risk Factors; Time Factors; Viral Load | 2014 |
Combinations of oseltamivir and fibrates prolong the mean survival time of mice infected with the lethal H7N9 influenza virus.
Topics: Animals; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Disease Models, Animal; Drug Therapy, Combination; Female; Fibric Acids; Influenza A Virus, H7N9 Subtype; Lung; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Survival; Virus Replication | 2015 |
The pathological effects of CCR2+ inflammatory monocytes are amplified by an IFNAR1-triggered chemokine feedback loop in highly pathogenic influenza infection.
Topics: Animals; Antiviral Agents; Chemokines; Disease Models, Animal; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Mice, Inbred C57BL; Monocytes; Orthomyxoviridae Infections; Oseltamivir; Receptor, Interferon alpha-beta; Receptors, CCR2; Severity of Illness Index; Specific Pathogen-Free Organisms; Virus Replication | 2014 |
The administration of oseltamivir results in reduced effector and memory CD8+ T cell responses to influenza and affects protective immunity.
Topics: Adaptive Immunity; Animals; Antibodies, Viral; Antiviral Agents; CD8-Positive T-Lymphocytes; Cells, Cultured; Female; Flow Cytometry; Immunologic Memory; Influenza A virus; Lung; Lymph Nodes; Mice; Mice, Inbred C57BL; Orthomyxoviridae Infections; Oseltamivir; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2015 |
In vitro evaluation of synergistic inhibitory effects of neuraminidase inhibitors and methylglyoxal against influenza virus infection.
Topics: Animals; Antiviral Agents; Dogs; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N2 Subtype; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyruvaldehyde; Virus Replication | 2015 |
Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
Topics: Acids, Carbocyclic; Adamantane; Amino Acid Substitution; Animals; Antiviral Agents; Base Sequence; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Genotype; Guanidines; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H1N2 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Mutation, Missense; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Phenotype; Phylogeny; Swine; Swine Diseases; Time Factors; United States; Viral Proteins; Zanamivir | 2015 |
A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity.
Topics: Animals; Antiviral Agents; Behavior, Animal; Female; Ferrets; Influenza A Virus, H1N1 Subtype; Male; Orthomyxoviridae Infections; Oseltamivir; Video Recording | 2015 |
Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Enzyme Inhibitors; Ferrets; Genes, Viral; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Male; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Respiratory Tract Infections; Virus Replication | 2015 |
Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
Topics: Acids, Carbocyclic; Administration, Intravenous; Animals; Antiviral Agents; Bacterial Load; Coinfection; Cyclopentanes; Cytokines; Disease Models, Animal; Dogs; Guanidines; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Pneumococcal Infections; Streptococcus pneumoniae; Viral Load; Virus Replication | 2015 |
A GFP expressing influenza A virus to report in vivo tropism and protection by a matrix protein 2 ectodomain-specific monoclonal antibody.
Topics: Animals; Antibodies, Monoclonal; Antiviral Agents; Cells, Cultured; Dendritic Cells; Dogs; Green Fluorescent Proteins; Influenza A virus; Madin Darby Canine Kidney Cells; Mice; Monocytes; Orthomyxoviridae Infections; Oseltamivir; Protein Stability; Recombinant Fusion Proteins; Viral Matrix Proteins; Viral Nonstructural Proteins; Viral Tropism; Virus Replication | 2015 |
[Anti-viral activity of a complex of the glycyrrhizic acid-alpha-glutamyltryptophan against the experimental lethal influenza infection in white mice caused by the oseltamivir-resistant strain of the virus].
Topics: Administration, Oral; Animals; Antiviral Agents; Dipeptides; Drug Combinations; Drug Resistance, Viral; Female; Glycyrrhizic Acid; Influenza A Virus, H1N1 Subtype; Lung; Mice; Orthomyxoviridae Infections; Oseltamivir; Survival Analysis; Viral Load | 2014 |
Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Influenza Vaccines; Influenza, Human; Macaca; Mice; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Primates; Vaccination; Viral Proteins; Virus Replication | 2015 |
Oseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza Viruses.
Topics: Adolescent; Adult; Animals; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Child; Child, Preschool; Female; Ferrets; Humans; Infant; Inflammation; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mice; Mice, Inbred C57BL; Orthomyxoviridae Infections; Oseltamivir; Viral Load; Young Adult | 2015 |
Coadministration of Hedera helix L. Extract Enabled Mice to Overcome Insufficient Protection against Influenza A/PR/8 Virus Infection under Suboptimal Treatment with Oseltamivir.
Topics: Animals; Antiviral Agents; Bronchoalveolar Lavage Fluid; Cytokines; Cytopathogenic Effect, Viral; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Hedera; In Vitro Techniques; Inflammation; Influenza A virus; Lung; Mice; Mice, Inbred C57BL; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Phytotherapy; Plant Extracts; Saponins | 2015 |
Oseltamivir inhibits influenza virus replication and transmission following ocular-only aerosol inoculation of ferrets.
Topics: Administration, Oral; Animals; Antiviral Agents; Disease Models, Animal; Ferrets; Male; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Survival Analysis; Virus Replication | 2015 |
Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors.
Topics: Animals; Antiviral Agents; Aza Compounds; Drug Evaluation, Preclinical; Drug Resistance, Viral; Gene Expression; Indoles; Influenza A Virus, H1N1 Subtype; Lung; Male; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Research Design; Respiratory Function Tests; Survival Analysis; Viral Proteins | 2015 |
Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Dogs; Drug Administration Schedule; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Injections, Intramuscular; Lung; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred C57BL; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Survival Analysis; Treatment Outcome; Viral Load; Viral Proteins; Virus Replication | 2015 |
A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A virus; Influenza, Human; Models, Molecular; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Point Mutation; Viral Proteins | 2016 |
Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.
Topics: A549 Cells; Acute Lung Injury; Animals; Antiviral Agents; Benzoates; DNA-Directed RNA Polymerases; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Viral; HEK293 Cells; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Male; Mice; Mice, Inbred ICR; Orthomyxoviridae Infections; Oseltamivir; Ribavirin; Virus Replication | 2016 |
Novel strategies for targeting innate immune responses to influenza.
Topics: Acute Lung Injury; Animals; Antiviral Agents; Disaccharides; Drug Synergism; Female; Gene Expression Regulation; HMGB1 Protein; Immunity, Innate; Immunoglobulin G; Interleukin-1 Receptor Accessory Protein; Lung; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Targeted Therapy; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Signal Transduction; Sugar Phosphates; Survival Analysis; Toll-Like Receptor 2; Toll-Like Receptor 4 | 2016 |
Within-Host Models of High and Low Pathogenic Influenza Virus Infections: The Role of Macrophages.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Viral; Antiviral Agents; B-Lymphocytes; Cell Death; Epithelial Cells; Host-Pathogen Interactions; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C; Models, Immunological; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Viral Load; Virulence; Zanamivir | 2016 |
The Effect of Oseltamivir on the Disease Progression of Lethal Influenza A Virus Infection: Plasma Cytokine and miRNA Responses in a Mouse Model.
Topics: Animals; Antiviral Agents; Biomarkers, Tumor; Cytokines; Disease Models, Animal; Disease Progression; Female; Gene Expression Regulation; Influenza A virus; Mice; MicroRNAs; Orthomyxoviridae Infections; Oseltamivir; Treatment Outcome; Viral Load | 2016 |
Forsythoside A Controls Influenza A Virus Infection and Improves the Prognosis by Inhibiting Virus Replication in Mice.
Topics: Animals; Antiviral Agents; Gene Expression Regulation; Glycosides; Influenza A virus; Lung; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Orthomyxoviridae Infections; Oseltamivir; Prognosis; Random Allocation; Real-Time Polymerase Chain Reaction; Signal Transduction; Toll-Like Receptor 7; Virus Replication; Weight Loss | 2016 |
Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice.
Topics: Amides; Animals; Dogs; Drug Therapy, Combination; Female; Influenza A Virus, H5N1 Subtype; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Pyrazines | 2016 |
Combination activity of neuraminidase inhibitor oseltamivir and α-tocopherol in influenza virus A (H3N2) infection in mice.
Topics: Administration, Oral; alpha-Tocopherol; Animals; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Structure-Activity Relationship | 2015 |
Efficacy of a specific polyclonal equine F(ab')2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir.
Topics: Animals; Antibodies, Viral; Antiviral Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Ferrets; Horses; Immunization, Passive; Immunoglobulin Fab Fragments; Influenza A Virus, H5N1 Subtype; Orphan Drug Production; Orthomyxoviridae Infections; Oseltamivir; Viral Load | 2016 |
Contact transmission of influenza virus between ferrets imposes a looser bottleneck than respiratory droplet transmission allowing propagation of antiviral resistance.
Topics: Animals; Antiviral Agents; Disease Transmission, Infectious; Dogs; Drug Resistance, Viral; Female; Ferrets; Genome, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Mutation; Orthomyxoviridae Infections; Oseltamivir; Respiratory System | 2016 |
Vaccination Is More Effective Than Prophylactic Oseltamivir in Preventing CNS Invasion by H5N1 Virus via the Olfactory Nerve.
Topics: Animals; Antiviral Agents; Chemoprevention; Disease Models, Animal; Female; Ferrets; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Injections, Intramuscular; Meningoencephalitis; Olfactory Nerve; Orthomyxoviridae Infections; Oseltamivir; Treatment Outcome | 2016 |
Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice.
Topics: Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Dogs; Enzyme Inhibitors; Female; Ferrets; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pandemics; Swine; Viral Proteins; Virulence; Virus Replication | 2016 |
Extracellular Matrix Proteolysis by MT1-MMP Contributes to Influenza-Related Tissue Damage and Mortality.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Extracellular Matrix; Female; Gene Expression Profiling; Genomics; Lung; Matrix Metalloproteinase 14; Mice; Mice, Inbred C57BL; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Protease Inhibitors; Proteolysis; Proteome; Proteomics; Survival Analysis; Treatment Outcome | 2016 |
Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice.
Topics: Animals; Antiviral Agents; Drug Discovery; Drug Therapy, Combination; Indoles; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Lung; Mice; Orthomyxoviridae Infections; Oseltamivir; Pyridines; Pyrimidines; Pyrroles; Viral Load; Virus Replication | 2016 |
The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Catalytic Domain; Computer Simulation; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Genetic Fitness; Guanidines; Influenza A Virus, H1N1 Subtype; Inhibitory Concentration 50; Mice; Molecular Dynamics Simulation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Reverse Genetics | 2017 |
Activity of ergoferon against lethal influenza A (H3N2) virus infection in mice.
Topics: Animals; Antibodies; Antiviral Agents; CD4 Antigens; Drug Administration Schedule; Drug Dosage Calculations; Female; Histamine; Immunologic Factors; Influenza A Virus, H3N2 Subtype; Interferon-gamma; Longevity; Lung; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Survival Analysis; Treatment Outcome; Viral Load | 2017 |
Severe acute respiratory infection caused by swine influenza virus in a child necessitating extracorporeal membrane oxygenation (ECMO), the Netherlands, October 2016.
Topics: Animals; Antiviral Agents; Extracorporeal Membrane Oxygenation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units, Pediatric; Netherlands; Orthomyxoviridae Infections; Oseltamivir; Real-Time Polymerase Chain Reaction; Respiratory Tract Infections; Severe Acute Respiratory Syndrome; Swine; Swine Diseases; Treatment Outcome | 2016 |
Combinations of 1,8-cineol and oseltamivir for the treatment of influenza virus A (H3N2) infection in mice.
Topics: Animals; Antiviral Agents; Cyclohexanols; Cytokines; Drug Synergism; Drug Therapy, Combination; Eucalyptol; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Interleukin-10; Lung; Mice; Monoterpenes; Orthomyxoviridae Infections; Oseltamivir; Tumor Necrosis Factor-alpha | 2017 |
Generation and characterization of new monoclonal antibodies against swine origin 2009 influenza A (H1N1) virus and evaluation of their prophylactic and therapeutic efficacy in a mouse model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Viral; Combined Modality Therapy; Dogs; Drug Synergism; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Immunodominant Epitopes; Immunotherapy; Influenza A Virus, H1N1 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Protein Multimerization; Swine; Viral Vaccines | 2017 |
A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Epitopes; Hemagglutinins; Humans; Hydrogen-Ion Concentration; Immunoglobulin G; Influenza B virus; Mice; Models, Molecular; Orthomyxoviridae Infections; Oseltamivir; Protein Conformation | 2017 |
Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza A virus H1N1.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Computer Simulation; Dogs; Drug Design; Drug Resistance, Viral; Enzyme Inhibitors; HeLa Cells; Humans; In Vitro Techniques; Influenza A Virus, H1N1 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Microscopy, Atomic Force; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Vero Cells; Viral Proteins | 2017 |
Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses.
Topics: Administration, Oral; Aerosols; Animals; Antiviral Agents; Disease Models, Animal; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H7N9 Subtype; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Survival Rate; Weight Loss | 2017 |
Anti-influenza virus activity of propolis in vitro and its efficacy against influenza infection in mice.
Topics: Administration, Oral; Animals; Antiviral Agents; Brazil; Bronchoalveolar Lavage Fluid; Female; Influenza A Virus, H1N1 Subtype; Lung; Mice; Mice, Inbred DBA; Orthomyxoviridae Infections; Oseltamivir; Propolis; Viral Load; Viral Plaque Assay; Weight Loss | 2008 |
Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.
Topics: Animals; Antiviral Agents; Chemokines; Cytokines; Drug Interactions; Drug Therapy, Combination; Female; Influenza A Virus, H5N1 Subtype; Lung; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Ribavirin; Virus Replication | 2008 |
Deletions of neuraminidase and resistance to oseltamivir may be a consequence of restricted receptor specificity in recent H3N2 influenza viruses.
Topics: Animals; Cell Line; Drug Resistance, Viral; Enzyme Inhibitors; Gene Deletion; Influenza A Virus, H3N2 Subtype; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Serial Passage; Substrate Specificity | 2009 |
[Therapeutic efficacy of Ingavirin, a new domestic formulation against influenza A virus (H3N2)].
Topics: Amides; Animals; Antiviral Agents; Caproates; Dicarboxylic Acids; Imidazoles; Indoles; Influenza A Virus, H3N2 Subtype; Lung; Mice; Orthomyxoviridae Infections; Oseltamivir; Rimantadine; Virus Replication | 2008 |
Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.
Topics: Amantadine; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Humans; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Orthomyxoviridae Infections; Oseltamivir; Ribavirin; Specific Pathogen-Free Organisms; Treatment Outcome | 2009 |
Effects of Clinacanthus siamensis leaf extract on influenza virus infection.
Topics: Acanthaceae; Animals; Antibodies, Viral; Antiviral Agents; Body Weight; Cell Line; Female; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Plant Extracts; Plant Leaves; Plants, Medicinal | 2009 |
Study of efficiency of therapeutic and preventive anaferon (pediatric formulation) in mice with influenza infection.
Topics: Administration, Intranasal; Animals; Antiviral Agents; Dose-Response Relationship, Drug; Female; Influenza A Virus, H3N2 Subtype; Interferon-gamma; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir | 2008 |
Can we "hedge" against the development of antiviral resistance among pandemic influenza viruses?
Topics: Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Drug Therapy, Combination; Health Policy; Humans; Influenza A Virus, H1N1 Subtype; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir | 2009 |
Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice.
Topics: Animals; Caffeine; Cell Line; Chickens; Dogs; Drug Combinations; Drug Evaluation, Preclinical; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir | 2009 |
Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.
Topics: Animals; Antiviral Agents; Asia, Southeastern; Australasia; Cell Line; Drug Resistance, Viral; Female; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2009 |
[Inquired of the President of the.Robert Koch Institute. How dangerous is Mexican influenza?].
Topics: Animals; Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Germany; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mexico; Orthomyxoviridae Infections; Oseltamivir; Swine; World Health Organization; Zanamivir | 2009 |
Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.
Topics: Amides; Animals; Antiviral Agents; Cell Line; Drug Combinations; Drug Interactions; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrazines | 2010 |
Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; Body Weight; Female; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Severity of Illness Index; Survival Analysis | 2009 |
Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Treatment Outcome; Zanamivir | 2010 |
Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Drug Resistance, Viral; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Mutation, Missense; Nasal Cavity; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Viral Plaque Assay; Virulence; Virus Replication | 2010 |
Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
Topics: Animals; Antiviral Agents; Female; Guanidines; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Pyrans; Sialic Acids; Zanamivir | 2010 |
Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus.
Topics: Animals; Antibodies, Viral; Antiviral Agents; Female; Immunity, Mucosal; Immunoglobulin A; Immunoglobulin G; Immunosuppression Therapy; Immunosuppressive Agents; Influenza A virus; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir | 2010 |
Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Influenza A Virus, H5N1 Subtype; Male; Mutation, Missense; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Recombination, Genetic; Respiratory System; Survival Analysis; Viral Proteins; Virulence; Virus Replication | 2010 |
Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.
Topics: Animals; Antiviral Agents; Cell Line; Crystallography; Disease Models, Animal; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Ferrets; Humans; Influenza A Virus, H5N1 Subtype; Kidney; Male; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Protein Structure, Tertiary; Recombinant Proteins; Zanamivir | 2010 |
Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Disease Models, Animal; DNA Mutational Analysis; Drug Resistance, Viral; Female; Ferrets; Humans; Influenza A Virus, H5N1 Subtype; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Viral Proteins; Zanamivir | 2010 |
Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Interactions; Drug Therapy, Combination; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir | 2010 |
Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Birds; Catalytic Domain; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza in Birds; Influenza, Human; Models, Molecular; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Protein Conformation; Species Specificity; Swine; Swine Diseases; Viral Proteins; Zanamivir | 2010 |
Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice.
Topics: Animals; Antiviral Agents; Cytokines; Female; Host-Pathogen Interactions; Immunity, Innate; Influenza A virus; Influenza A Virus, H5N1 Subtype; Lung; Mice; Mice, Inbred BALB C; Mice, Knockout; Orthomyxoviridae Infections; Oseltamivir; RNA, Double-Stranded; Toll-Like Receptor 3; Virus Replication | 2010 |
Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets.
Topics: Animals; Base Sequence; Cell Line; Disease Outbreaks; Dogs; Drug Resistance, Viral; Ferrets; Genome, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir | 2010 |
Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models.
Topics: Animals; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Guinea Pigs; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2010 |
Inhibition of influenza virus replication by plant-derived isoquercetin.
Topics: Amantadine; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Drug Evaluation, Preclinical; Drug Resistance, Viral; Drug Synergism; Equisetum; Female; Humans; Hypericum; Influenza A virus; Influenza B virus; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Plant Extracts; Quercetin; Vero Cells; Virus Replication | 2010 |
Correlation analyses on binding affinity of sialic acid analogues with influenza virus neuraminidase-1 using ab initio MO calculations on their complex structures.
Topics: Animals; Antiviral Agents; Binding Sites; Humans; Influenza A virus; Models, Molecular; N-Acetylneuraminic Acid; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Protein Binding | 2010 |
Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Female; Ferrets; Influenza A Virus, H1N1 Subtype; Male; Mice; Mice, Inbred BALB C; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pandemics; Virus Replication | 2010 |
Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice.
Topics: Animals; CD8 Antigens; CD8-Positive T-Lymphocytes; Cells, Cultured; Dogs; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Lung Diseases; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Orthomyxoviridae Infections; Oseltamivir; Prognosis; Virus Replication | 2010 |
[In vivo efficacy of Ingavirin against pandemic A (H1N1/09)v influenza virus].
Topics: Amides; Animals; Antiviral Agents; Caproates; Dicarboxylic Acids; Female; Imidazoles; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Lung; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Rimantadine; Virus Replication | 2010 |
[Prophylactic and therapeutic efficacies of Ingavirin, a novel Russian chemotherapeutic, with respect to influenza pathogen A (H5N1)].
Topics: Amides; Animals; Antiviral Agents; Caproates; Dicarboxylic Acids; Humans; Imidazoles; Indoles; Influenza A Virus, H5N1 Subtype; Influenza, Human; Mice; Mice, Inbred Strains; Orthomyxoviridae Infections; Oseltamivir | 2010 |
Antiviral activity of Anaferon (pediatric formulation) in mice infected with pandemic influenza virus A(H1N1/09).
Topics: Animals; Antibodies; Antiviral Agents; Influenza A Virus, H1N1 Subtype; Lung; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir | 2010 |
Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Asparagine; Disease Models, Animal; Drug Resistance, Viral; Female; Ferrets; Influenza A Virus, H5N1 Subtype; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Point Mutation; Rodent Diseases; Serine; Survival Analysis; Treatment Outcome; Viral Proteins; Virulence; Virulence Factors; Virus Replication; Zanamivir | 2011 |
Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.
Topics: Administration, Oral; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Dogs; Drug Resistance, Viral; Female; Ferrets; Influenza A Virus, H1N1 Subtype; Lung; Microbial Sensitivity Tests; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Oxygen; Pneumonia, Viral; Viral Load; Viral Plaque Assay; Virus Replication | 2011 |
Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
Topics: Animals; Antiviral Agents; Cell Line; Drug Resistance, Viral; Enzyme Inhibitors; Germany; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H1N2 Subtype; Influenza A Virus, H3N2 Subtype; Microbial Sensitivity Tests; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Swine; Swine Diseases; Zanamivir | 2012 |
Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus.
Topics: Alternaria; Animals; Bronchoalveolar Lavage Fluid; Cell Line; Cytokines; Dogs; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Immunomodulation; Influenza A virus; Male; Mice; Mice, Inbred C57BL; Neutralization Tests; Orthomyxoviridae Infections; Oseltamivir; Sphingosine | 2011 |
Biotin-, fluorescein- and 'clickable' conjugates of phospha-oseltamivir as probes for the influenza virus which utilize selective binding to the neuraminidase.
Topics: Antiviral Agents; Biotin; Click Chemistry; Enzyme Inhibitors; Fluorescein; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Protein Binding | 2011 |
Quercetin 3-rhamnoside exerts antiinfluenza A virus activity in mice.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Influenza A virus; Lung; Male; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Phytotherapy; Quercetin; Viral Load; Virus Cultivation; Weight Loss | 2012 |
Effects of TheraMax on influenza virus infections in cell culture and in mice.
Topics: Administration, Intranasal; Animals; Antiviral Agents; Camellia sinensis; Cell Line; Dogs; Drug Evaluation, Preclinical; Hemorrhage; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza B virus; Lung; Lung Diseases; Mice; Mice, Inbred BALB C; Nasal Cavity; Orthomyxoviridae Infections; Oseltamivir; Plant Extracts; Sambucus; Toxicity Tests; Weight Loss | 2011 |
Competitive transmissibility and fitness of oseltamivirsensitive and resistant pandemic influenza H1N1 viruses in ferrets.
Topics: Animals; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Orthomyxoviridae Infections; Oseltamivir; Sequence Analysis, DNA; Viral Proteins | 2011 |
Interactions of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Genetic Fitness; Genetic Variation; Influenza A Virus, H5N1 Subtype; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Virulence | 2011 |
Inhibitory effect and possible mechanism of action of patchouli alcohol against influenza A (H2N2) virus.
Topics: Administration, Oral; Animals; Antiviral Agents; Binding Sites; Cell Line; Cell Survival; Dogs; Influenza A Virus, H2N2 Subtype; Inhibitory Concentration 50; Mice; Mice, Inbred Strains; Molecular Dynamics Simulation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Protein Binding; Protein Interaction Domains and Motifs; Protein Structure, Secondary; Sesquiterpenes; Survival Rate; Thermodynamics; Virus Replication | 2011 |
Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets.
Topics: Air Microbiology; Animals; Antiviral Agents; Disease Models, Animal; Disease Transmission, Infectious; Drug Resistance, Viral; Ferrets; Influenza A Virus, H1N1 Subtype; Male; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pandemics; Time Factors; Viral Load; Virus Replication | 2011 |
Use of plethysmography in assessing the efficacy of antivirals in a mouse model of pandemic influenza A virus.
Topics: Animals; Antiviral Agents; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Influenza A Virus, H1N1 Subtype; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Plethysmography; Ribavirin; Treatment Outcome | 2011 |
High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals.
Topics: Administration, Intranasal; Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Female; Guanidines; Influenza A virus; Inhibitory Concentration 50; Lung; Mice; Mice, Inbred BALB C; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Viral Load; Zanamivir | 2012 |
Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Ducks; Influenza A Virus, H1N1 Subtype; Mutation; Orthomyxoviridae Infections; Oseltamivir | 2011 |
The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses.
Topics: Adult; Amino Acid Substitution; Animals; Antibodies, Monoclonal; Antiviral Agents; Cell Line; Drug Resistance, Viral; Female; Genotype; Humans; Influenza A Virus, H1N1 Subtype; Mice; Mice, Inbred BALB C; Middle Aged; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Phylogeny; Viral Proteins; Young Adult | 2012 |
Tamiflu-resistant but HA-mediated cell-to-cell transmission through apical membranes of cell-associated influenza viruses.
Topics: Animals; Antibodies, Neutralizing; Base Sequence; Cell Line; Cell Membrane; Cell Polarity; Dogs; Drug Resistance, Viral; HEK293 Cells; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza, Human; Molecular Sequence Data; Movement; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir | 2011 |
Influenza and obesity: will vaccines and antivirals protect?
Topics: Animals; Antibodies, Viral; Antiviral Agents; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Lung; Male; Obesity; Orthomyxoviridae Infections; Oseltamivir | 2012 |
Impaired wound healing predisposes obese mice to severe influenza virus infection.
Topics: Albumins; Animals; Antiviral Agents; Bronchoalveolar Lavage Fluid; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Kaplan-Meier Estimate; Ki-67 Antigen; Leukocyte Count; Lung; Male; Mice; Mice, Inbred C57BL; Models, Animal; Monocytes; Neutrophil Infiltration; Obesity; Orthomyxoviridae Infections; Oseltamivir; Pulmonary Edema; Severity of Illness Index; Viral Load; Wound Healing | 2012 |
Oseltamivir inhibits H7 influenza virus replication in mice inoculated by the ocular route.
Topics: Animals; Antiviral Agents; Conjunctivitis; Eye; Humans; Influenza A Virus, H7N3 Subtype; Influenza A Virus, H7N7 Subtype; Influenza, Human; Injections, Intraocular; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Viral Proteins; Virus Replication; Vision, Ocular | 2012 |
Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Ferrets; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pandemics; Reverse Genetics; Viral Proteins; Virus Replication; Zanamivir | 2012 |
Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A/California/04/2009 (H1N1).
Topics: Animals; Bronchoalveolar Lavage Fluid; Chemokines; Cytokines; DNA Primers; Female; Influenza A Virus, H1N1 Subtype; Kaplan-Meier Estimate; Lung; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Real-Time Polymerase Chain Reaction; Ribavirin | 2012 |
A secondary sialic acid binding site on influenza virus neuraminidase: fact or fiction?
Topics: Animals; Antiviral Agents; Binding Sites; Humans; Models, Molecular; N-Acetylneuraminic Acid; Neuraminidase; Nuclear Magnetic Resonance, Biomolecular; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir | 2012 |
Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses.
Topics: Amantadine; Animals; Antiviral Agents; Cells, Cultured; Disease Models, Animal; Dogs; Drug Combinations; Drug Resistance, Viral; Drug Synergism; Female; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Placebos; Ribavirin; Treatment Outcome | 2012 |
Efficient transmission of pandemic H1N1 influenza viruses with high-level oseltamivir resistance.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Guinea Pigs; Influenza A Virus, H1N1 Subtype; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir | 2012 |
Enhanced mammalian transmissibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Female; Guinea Pigs; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Sequence Data; Mutation, Missense; Neuraminidase; New York; Orthomyxoviridae Infections; Oseltamivir; Reverse Genetics; RNA, Viral; Sequence Analysis, DNA; Viral Proteins | 2012 |
Prophylactic and therapeutic combination effects of rimantadine and oseltamivir against influenza virus A (H3N2) infection in mice.
Topics: Animals; Antiviral Agents; Chemoprevention; Disease Models, Animal; Drug Therapy, Combination; Influenza A Virus, H3N2 Subtype; Lung; Male; Mice; Mice, Inbred ICR; Orthomyxoviridae Infections; Oseltamivir; Pneumonia, Viral; Rimantadine; Viral Load | 2012 |
Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Female; Guanidines; Influenza A Virus, H1N1 Subtype; Injections, Intramuscular; Mice; Mice, Inbred BALB C; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Treatment Outcome; Viral Proteins | 2012 |
Airborne transmission of influenza A/H5N1 virus between ferrets.
Topics: Air Microbiology; Amino Acid Substitution; Animals; Antiviral Agents; Containment of Biohazards; Disease Models, Animal; Female; Ferrets; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Immune Sera; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Orthomyxoviridae Infections; Oseltamivir; Pandemics; Poultry; Reassortant Viruses; Receptors, Virus; Respiratory System; Reverse Genetics; RNA-Dependent RNA Polymerase; Serial Passage; Sialic Acids; Viral Proteins; Virulence; Virus Replication; Virus Shedding | 2012 |
Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.
Topics: Amantadine; Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Female; Influenza A Virus, H1N1 Subtype; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Survival Analysis; Treatment Outcome | 2012 |
Oral clarithromycin enhances airway immunoglobulin A (IgA) immunity through induction of IgA class switching recombination and B-cell-activating factor of the tumor necrosis factor family molecule on mucosal dendritic cells in mice infected with influenza
Topics: Administration, Oral; Animals; Antibodies, Neutralizing; Antiviral Agents; B-Cell Activating Factor; Bronchi; Clarithromycin; Cytidine Deaminase; Dendritic Cells; Female; Immunity, Mucosal; Immunoglobulin A; Immunoglobulin Class Switching; Influenza A Virus, H1N1 Subtype; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Spleen; Tumor Necrosis Factor-alpha | 2012 |
Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir.
Topics: Animals; Antiviral Agents; Cell Line; Defective Viruses; Ferrets; Hemagglutination Inhibition Tests; Influenza A Virus, H1N1 Subtype; Male; Nasal Lavage Fluid; Orthomyxoviridae Infections; Oseltamivir; RNA, Viral; Transfection; Weight Loss | 2012 |
Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the neuraminidase of subtype H5N1 avian influenza A viruses.
Topics: Animals; Antiviral Agents; Birds; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Point Mutation; Poultry; Viral Proteins; Virus Replication | 2013 |
Anti-influenza A virus characteristics of a fucoidan from sporophyll of Undaria pinnatifida in mice with normal and compromised immunity.
Topics: Animals; Antiviral Agents; Body Weight; Disease Models, Animal; Immunocompromised Host; Influenza A virus; Mice; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Polysaccharides; Survival Analysis; Treatment Outcome; Undaria; Virus Replication | 2013 |
Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae.
Topics: Acetamides; Animals; Bacterial Adhesion; Cell Line; Disease Models, Animal; Enzyme Inhibitors; Epithelial Cells; Female; Lung; Mice; Mice, Inbred BALB C; N-Acetylneuraminic Acid; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Pneumonia, Pneumococcal; Streptococcus pneumoniae | 2003 |
Infectious diseases. Avian flu outbreak sets off alarm bells.
Topics: Acetamides; Animals; Antiviral Agents; Chickens; Conjunctivitis, Viral; Disease Outbreaks; Humans; Influenza A virus; Influenza in Birds; Influenza Vaccines; Influenza, Human; Netherlands; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Recombination, Genetic; Swine; Vaccination | 2003 |
Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model.
Topics: Acetamides; Animals; Antiviral Agents; Disease Models, Animal; Drug Therapy, Combination; Glucocorticoids; Guanidines; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Rats; Sialic Acids; Sigmodontinae; Triamcinolone Acetonide; Zanamivir | 2003 |
Influenza-induced rhabdomyolysis after autologous peripheral blood stem cell transplantation for malignant lymphoma.
Topics: Acetamides; Aged; Antiviral Agents; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Influenza A virus; Lymphoma, T-Cell; Male; Orthomyxoviridae Infections; Oseltamivir; Peripheral Blood Stem Cell Transplantation; Rhabdomyolysis; Transplantation, Autologous | 2003 |
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.
Topics: Acetamides; Amides; Animals; Antiviral Agents; Drug Evaluation, Preclinical; Influenza A virus; Mice; Orthomyxoviridae Infections; Oseltamivir; Pyrazines; Survival Rate; Time Factors | 2003 |
Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza.
Topics: Acetamides; Ampicillin; Animals; Anti-Bacterial Agents; Antiviral Agents; Bacterial Adhesion; Cell Line; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Female; Influenza A virus; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Treatment Outcome | 2004 |
Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.
Topics: Acetamides; Amino Acid Substitution; Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Influenza A virus; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Viral Proteins | 2004 |
Treatment of mannan-enhanced influenza B virus infections in mice with oseltamivir, ribavirin and viramidine.
Topics: Acetamides; Administration, Oral; Animals; Antiviral Agents; Dose-Response Relationship, Drug; Hong Kong; Influenza B virus; Lung; Mannans; Mice; Organ Size; Orthomyxoviridae Infections; Oseltamivir; Ribavirin; Survival Rate | 2004 |
Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo.
Topics: Acetamides; Acids, Carbocyclic; Administration, Intranasal; Administration, Oral; Animals; Antiviral Agents; Cyclopentanes; Dose-Response Relationship, Drug; Guanidines; Mice; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Structure-Activity Relationship; Survival Rate; Treatment Outcome; Zanamivir | 2005 |
Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.
Topics: Acetamides; Animals; Antiviral Agents; Brain; Cell Line; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Guanidines; Influenza A virus; Inhibitory Concentration 50; Lung; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Virulence; Virus Replication; Zanamivir | 2005 |
Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.
Topics: Acetamides; Amino Acid Substitution; Animals; Cell Line; Coculture Techniques; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Viral; Drug Tolerance; Enzyme Inhibitors; Enzyme Stability; Female; Ferrets; Genetic Variation; Guanidines; Kinetics; Mutagenesis, Site-Directed; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Recombination, Genetic; Sialic Acids; Temperature; Virus Replication; Zanamivir | 2005 |
Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection.
Topics: Acetamides; Amino Acid Substitution; Animals; Disease Models, Animal; Drug Resistance, Viral; Immunocompetence; Immunocompromised Host; Influenza A virus; Mice; Mice, Inbred BALB C; Mice, SCID; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrrolidines | 2006 |
Oseltamivir becomes plentiful--but still not cheap.
Topics: Acetamides; Animals; Antiviral Agents; Chemistry, Pharmaceutical; Developing Countries; Drug Costs; Drug Industry; Drugs, Generic; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Orthomyxoviridae Infections; Oseltamivir; Patents as Topic; Randomized Controlled Trials as Topic | 2006 |
Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses.
Topics: Administration, Oral; Animals; Antiviral Agents; Cells, Cultured; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Influenza A Virus, H1N1 Subtype; Influenza B virus; Mice; Orthomyxoviridae Infections; Oseltamivir; Placebos; Ribavirin; Time Factors | 2006 |
Seasonal and pandemic influenza preparedness: science and countermeasures.
Topics: Academies and Institutes; Adult; Animals; Antiviral Agents; Clinical Trials as Topic; Disease Outbreaks; Drug Therapy, Combination; Enzyme Inhibitors; Global Health; Health Planning; Humans; Infant; Influenza A virus; Influenza Vaccines; Influenza, Human; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Seasons; United States; Vaccination | 2006 |
Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice.
Topics: Administration, Oral; Animals; Antiviral Agents; Cell Line; Cells, Cultured; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Influenza A Virus, H3N2 Subtype; Lung; Male; Mice; Mice, Inbred ICR; Orthomyxoviridae Infections; Oseltamivir; Rimantadine; Structure-Activity Relationship; Survival Rate | 2006 |
Clinical pharmacokinetics of oseltamivir and its active metabolite oseltamivir carboxylate after oral administration in horses.
Topics: Administration, Oral; Animals; Dose-Response Relationship, Drug; Female; Horse Diseases; Horses; Male; Molecular Structure; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Time Factors | 2007 |
Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
Topics: Administration, Oral; Amantadine; Animals; Antiviral Agents; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Viral; Drug Therapy, Combination; Female; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Orthomyxoviridae Infections; Oseltamivir | 2007 |
Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice.
Topics: Amantadine; Animals; Antiviral Agents; Cell Line; Dogs; Dose-Response Relationship, Drug; Drug Combinations; Female; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir | 2007 |
Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1).
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Ferrets; Guanidines; Influenza A Virus, H5N1 Subtype; Injections, Intramuscular; Lung; Mice; Orthomyxoviridae Infections; Oseltamivir; Survival Analysis; Treatment Outcome | 2008 |
Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model.
Topics: Administration, Oral; Animals; Antiviral Agents; Disease Models, Animal; Ferrets; Influenza A Virus, H5N1 Subtype; Orthomyxoviridae Infections; Oseltamivir | 2008 |
Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
Topics: Acetamides; Administration, Oral; Amines; Animals; Antiviral Agents; Disease Models, Animal; Female; Ferrets; Guanidines; Influenza A virus; Influenza B virus; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Pyrans; Rats; Rats, Sprague-Dawley; Sialic Acids; Virus Replication; Zanamivir | 1998 |
Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.
Topics: Acetamides; Administration, Oral; Amines; Animals; Antiviral Agents; Biological Availability; Dogs; Dose-Response Relationship, Drug; Ferrets; Hydrolysis; Mice; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Rats; Rats, Sprague-Dawley; Time Factors | 1998 |
Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice.
Topics: Acetamides; Administration, Oral; Animals; Antigens, Surface; Antiviral Agents; Cytotoxicity, Immunologic; Enzyme Inhibitors; Female; Immune System; Killer Cells, Natural; Lymphocyte Subsets; Macrophages; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Spleen; Survival Rate; T-Lymphocytes, Cytotoxic | 2000 |
In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201.
Topics: Acetamides; Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Disease Models, Animal; Female; Guanidines; Influenza A virus; Influenza B virus; Lung; Mice; Mice, Inbred C57BL; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Respiratory Function Tests; Ribavirin; Virus Replication | 2001 |
Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Topics: Acetamides; Acids, Carbocyclic; Administration, Intranasal; Administration, Oral; Animals; Antiviral Agents; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Species Specificity; Survival Analysis; Time Factors; Zanamivir | 2001 |
Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Topics: Acetamides; Acids, Carbocyclic; Animals; Antiviral Agents; Body Weight; Brain; Cyclopentanes; Disease Models, Animal; Dogs; Female; Guanidines; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H9N2 Subtype; Lung; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Virus Replication; Zanamivir | 2001 |
Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection.
Topics: Acetamides; Acids, Carbocyclic; Animals; Antiviral Agents; Area Under Curve; Body Temperature; Cell Count; Cyclopentanes; Enzyme Inhibitors; Ferrets; Guanidines; Half-Life; Hemagglutination Inhibition Tests; Influenza A virus; Lung; Male; Nasal Cavity; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir | 2002 |
Utilization of alpha-1-acid glycoprotein levels in the serum as a parameter for in vivo assay of influenza virus inhibitors.
Topics: Acetamides; Animals; Antiviral Agents; Biomarkers; Female; Lung; Mice; Mice, Inbred BALB C; Orosomucoid; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Radioimmunoassay; Ribavirin; Time Factors | 2001 |